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1 Introduction 
Reactive oxygen species (ROS) are ubiquitous reactive derivatives of oxygen 
metabolism found in all aerobic biological system. ROS include free radical and 
non-radical species that oxidize molecular targets to change important cellular 
functions. Most important ROS include superoxide anion (·O2–), hydrogen 
peroxide (H2O2), hydroxyl anion (·OH) and reactive nitrogen species [e.g. nitric 
oxide (NO), peroxynitrite (ONOO-)]. All vascular cell types (endothelial cells, 
smooth muscle cells, and adventitial fibroblast) produce ROS. Physiologically, 
ROS are produced at low concentrations as signalling molecules, which do not 
disturb vascular integrity and are involved in regulating endothelial function and 
vascular contraction-relaxation. Under pathological conditions, increased ROS 
may lead to cardiovascular dysfunction as observed e.g. in hypertension, diabetes 
mellitus, atherosclerosis, ischemia–reperfusion injury, ischemic heart disease, and 
congestive cardiac failure (Landmesser & Harrison, 2001). In order to introduce 
the mediations of ROS in the vascular cells, in the next chapter 1) functional 
anatomy of arteries and 2) mechanisms of oxidative stress will be shortly 
described. 
 
1.1 Regulation of Arterial Contraction 
1.1.1 Structure of Arteries and Functional Interactions 
All blood vessels have the same basic structure. The tunica intima is the inner 
layer of arteries and veins. In arteries this layer is composed of an elastic 
membrane lining and smooth endothelium. The tunica media is the middle layer of 
the walls of arteries. It is composed of smooth muscle and elastic fibers. The main 
function of vascular smooth muscle is to regulate the tone of the blood vessels in 
the body. The tunica adventitia is the strong outer covering. It is composed of 
connective tissue as well as collagen and elastic fibers. These fibers allow the 
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arteries to stretch to prevent overexpansion due to the pressure that is exerted on 
the walls by blood flow. 
 
Endothelial cells as the luminal surface of the blood vessel have important 
antithrombosis protections. Furthermore, endothelial cells synthesize and release 
various factors that modulate in short terms vascular tone, in long terms 
atherosclerosis, angiogenesis and inflammation. The vasoactive factors include 
relaxing substances [prostacyclin (PGI2), nitric oxide (NO), C-natriuretic peptide 
(CNP),] and contracting substances [e.g. thromboxane A2 (TXA2), endothelin-1, 
angiotensin II (AngII), superoxide anion (·O2–)]. H2O2 generated by endothelium is 
recently found not only to be a vasoconstrictor but also to be a relaxing factor. 
Endothelial cells also communicate directly with smooth muscle cells via 
myoendothelial gap junctions. This communication allows not only the spread of 
electrotonic tone [such as endothelium-dependent hyperpolarizations, i.e., 
endothelium-derived hyperpolarizing factor (EDHF)-mediated responses] but also 
the transfer of ions or small molecules such as calcium and cyclic nucleotides 
(Feletou & Vanhoutte, 2006). Fig 1 shows the effects of endothelium-derived 
mediators on the arterial smooth muscle (Rang et al., 2003). 
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Fig 1 Endothelium-derived mediators. The picture shows some of the more important 
endothelium-derived contracting and relaxing mediators. (AI, II, angiotensin I, II; ACE, 
angiotensin-converting enzyme; AT1, angiotensin AT1-receptor; TP, T prostanoid 
receptor; ETA/(B), endothelin A (and B) receptors; NPR, natriuretic peptide receptor; IP, I 
prostanoid receptor; KIR, inward rectifying potassium channel; Na+/K+ ATPase, 
electrogenic pump; Gq, G-protein; IP3, inositol 1,4,5-trisphosphate; DAG, diacylglycerol; 
IL-1, interleukin 1; ACh, acetylcholine; BK, bradykinin; 5-HT, 5-hydroxytryptamine; 
EDHP, endothelium-derived hyperpolarising factor; PG, prostaglandin; CNP, 
C-natriuretic peptide; ET-1, endothelin 1. According to (Rang et al., 2003). 
 
Additionally, the vascular tone in active tissues is regulated not only by locally 
produced vasodilator metabolites (e.g. decreases in O2 and pH, increases in CO2) 
but also by circulating substances (e.g. bradykinin and the atrial natriuretic peptide) 
and the sympathetic nervous system that innervates the arteries. 
 
1.1.2 Contraction Mechanisms of Smooth Muscle 
Smooth muscle contraction is caused by the sliding of myosin and actin filaments 
over each other. There are two pathways to induce smooth muscle contraction, 
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including Ca2+-dependent pathways and Ca2+ sensitization pathways. The 
Ca2+-dependent pathways lead to increase intracellular Ca2+ through voltage-gated 
Ca2+ channels as well as Ca2+ release from the sarcoplasmic reticulum (Horowitz 
et al., 1996;Somlyo & Somlyo, 2003). Smooth muscle cells also store Ca2+ in the 
sarcoplasmic reticulum (SR), from which Ca2+ can be released when the IP3 
receptors are activated. The IP3 is generated by activation of many types of 
G-protein-coupled receptors. Thus, Ca2+ release and contraction can occur in 
smooth muscle without the involvement of electrical events and Ca2+ entry 
through the plasma membrane. Ca2+ binds to calmodulin (CaM), which activates 
myosin light chain kinase (MLCK). Activated MLCK leads to phosphorylation of 
20-kDa myosin light chains (MLC20). MLC20-P binds to actin and contraction is 
produced by crossbridge-cycling. MLC20-P can be dephosphorylated by myosin 
light chain phosphatase (MLCP), leading to relaxation. 
 
Ca2+ sensitization pathways are defined as increases in generated force without 
increases in intracellular Ca2+ (Somlyo & Somlyo, 2003). These pathways lead to 
an increase in MLC20-P through direct phosphorylation or inhibition of MLCP. 
There are some cell signalling pathways to regulate these mechanisms: Rho kinase 
(ROCK) pathway, protein kinase C (PKC), and zip kinase pathway (Fig 2). 
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Fig 2 Signal transduction mechanisms of smooth muscle contraction. (R, receptors; 
VOCC, voltage-operated calcium channels; SOCC, store-operated Ca2+ channels; SR, 
sarcoplasmic reticulum; MLC20, myosin light chain 20; Ca2+-CaM-MLCK, 
Ca2+-calmodulin-myosin light chain kinase; MLCP, myosin light chain phosphatase; 
ZIP-K, zipper-interacting protein kinase. According to (Ardanaz & Pagano, 2006). 
 
1.2 Reactive Oxygen Species in the Vasculature 
1.2.1 ROS Generation in Vessels 
1.2.1.1 NAD(P)H Oxidase 
The major source of ROS in all cells of the blood vessels is a 
superoxide-producing NAD(P)H oxidase. NAD(P)H oxidase is a multi-subunit 
enzyme, which utilizes NADH/NADPH as the electron donor to reduce molecular 
oxygen and produce ·O2– : 2O2 + NAD(P)H → 2·O2–  + NADP+ + H+. 
 
Vascular NAD(P)H oxidase is regulated by humoral (cytokines, growth factors, 
and vasoactive agents) and physical factors (stretch, pulsatile strain, and shear 
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stress). NAD(P)H oxidase generates superoxide in response of intracellular Ca2+ 
elevations since Ca2+ binds to the subunit of NAD(P)H oxidase. Physiologically, 
NAD(P)H oxidase produces ·O2– intracellularly in a slow and sustained fashion 
and ·O2– acts as intracellular signalling molecules (Lassegue & Clempus, 2003). 
 
1.2.1.2 NOS 
Nitric oxide synthase (NOS) normally generates NO, but can cause “uncoupling” 
in the context of deficiency of the essential NOS cofactor BH4 
(tetrahydrobiopterin). NOS uncoupling leads to decrease in NO production and 
increase in NOS-dependent ·O2– formation (Milstien & Katusic, 1999). eNOS 
uncoupling has been demonstrated in atherosclerosis (Vasquez-Vivar et al., 2002), 
diabetes (Bagi & Koller, 2003), hyperhomocysteinemia (Virdis et al., 2003), and 
hypertension (Landmesser et al., 2003). In hypertension, Landmesser et al  have 
showed that increased NAD(P)H oxidase-derived ·O2– leads to augmented ROS 
bioavailability, which causes oxidation of BH4 and consequent uncoupling of 
eNOS, contributing to ROS production (Landmesser et al., 2003). Since ·O2– 
derived from NOS is associated with marked endothelial dysfunction, NOS versus 
NAD(P)H oxidase-mediated ·O2– generation is probably related to endothelial 
dysfunction in hypertension. 
 
1.2.1.3 Xanthine Oxidase 
Xanthine oxidase is expressed on the luminal surface of the endothelium in many 
organs and catalyzes the oxidation of hypoxanthine and xanthine to form ·O2– in 
the vascular endothelium. Some evidences suggest xanthine oxidase is also 
involved in endothelium dysfunction in hypertension (Mervaala et al., 2001). In 
addition to effects on the vasculature, xanthine oxidase may play a role in 
end-organ damage in hypertension and reperfusion injury after ischemia (Laakso 
et al., 2004). 
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Other enzymatic sources of generating ROS in the vasculature are cyclooxygenase, 
cytochrome P450, mitochondrial respiratory chain and lipoxygenase, which may 
play a role in vascular function and dysfunction (Fleming et al., 2001;Kukreja et 
al., 1986). The sources of ROS in vascular cells are shown in Fig 3. 
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Fig 3 ROS generation in vascular cells. The ROS production is mainly from NAD(P)H 
oxidase, uncoupled NOS, and xanthine oxidase. According to (Touyz & Schiffrin, 2004). 
 
1.2.1.4 Inflammatory Reaction 
Activation of macrophages and leukocytes elicits the oxidative burst reaction with 
abundant secretion of ROS (Nguyen-Khoa et al., 1999).Under chronic conditions 
these alterations seem to be part of atherosclerotic plaque development. Especially 
the formation of oxidative modified LDL represents an important mechanism 
(Chisolm & Steinberg, 2000;Glass & Witztum, 2001). 
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1.2.2 Metabolism of ROS 
Reactive oxygen species are formed as intermediates in reduction–oxidation 
(redox) processes, leading from oxygen to water (Fridovich, 1997). In the presence 
of free electrons (e-), the univalent reduction of oxygen yields superoxide anion 
(·O2–), hydrogen peroxide (H2O2), and hydroxyl radical (·OH) (Fig 3). Since ·O2– 
has an unpaired electron, it is highly reactive, unstable and short-lived. In 
physiological conditions, ·O2– is dismutated to yield H2O2 by superoxide dismutase 
(SOD). However, a significant amount of ·O2– reacts with NO to produce ONOO– 
when it is produced in excess (Darley-Usmar et al., 1995). ·O2– is 
membrane-impermeable, but can cross cell membranes via anion channels 
(Schafer & Buettner, 2001). 
 
H2O2 is produced mainly from dismutation of ·O2– by superoxide dismutase (SOD). 
Unlike ·O2–, H2O2 is not a free radical. It is a much more stable and longer lived 
than ·O2–. In biological systems, it is scavenged by catalase and glutathione 
peroxidase (Schafer & Buettner, 2001). In the presence of molecules containing 
metal such as Fe2+, H2O2 can be reduced to generate ·OH (Haber-Weiss or Fenton 
reaction) (Fridovich, 1997). ·OH is extremely reactive. However, ·OH induces 
local damage where it is formed since it cannot travel some distance from the site 
of generation. 
 
Since H2O2 can cross cell membranes and produces cellular oxidative damage, it 
has been used as a model of oxidative stress (Rubanyi, 1988). H2O2 has complex 
effects on the vessels. It is able to modify vascular tone by inducing either 
contraction or relaxation, which is dependent on the different vascular beds and 
experimental conditions. For endothelium, H2O2 induces endothelial barrier 
dysfunction by modifying the sodium-potassium pump activity (Meharg et al., 
1993) and altering endothelial metabolic function (Fisher et al., 2002). However, it 
is suggested that H2O2 should be an endothelium-derived hyperpolarizing factor 
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(EDHF), inducing hyperpolarization and relaxation by activating KCa and 
ATP-sensitive K+ channels (Barlow & White, 1998;Barlow et al., 2000). 
 
1.2.3 Signalling Pathways 
ROS have multiple effects on vascular cells through involvement in many signal 
transduction pathways (Fig 4), while the exact molecular targets are not yet clear. 
ROS inactivate mitogen-activated protein kinases (MAPK) and protein tyrosine 
kinases (PTK) through oxidation/reduction of proteins. ROS stimulate Ca2+ and K+ 
channels. Additionally, ROS influence gene and protein expression by activating 
transcription factors [e.g. NFκB, activator protein-1 (AP-1)]. Activation of these 
pathways contributes to hypertensive vascular damage (Paravicini & Touyz, 2006). 
2O2 2·O2- 2H2O2 2H2O + O2
ROS
Ion channels
(Ca2+, K+)
Transcription factors 
(NFκB, AP-1)
PTK
Contraction
Migration
Inflammation Cell growth, Apoptosis
Endothelial dysfunction
Vascular remodeling
Altered tone
Vascular inflammation
MAPK
 
Fig 4 ROS signalling pathways in vascular smooth muscle cells. PTK, protein 
tyrosine kinases; MAPK, mitogen-activated kinases; ROS influence different signalling 
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pathways, altering vascular functions and pathologically leading to vascular damage. 
According to (Paravicini & Touyz, 2006). 
 
1.2.4 Antioxidant Defences 
Oxidative modifications within the arterial wall may contribute to diseases when 
the balance between oxidants and antioxidants shifts in favour of the former. 
Therefore, it is important to consider sources of available antioxidants. An 
antioxidant is defined as a substance that is effective against oxidative damage 
when present in much smaller quantity than the substance that it protects. The 
following briefly describes the antioxidant defences in arterial wall cells. 
 
1.2.4.1 Enzymatic Antioxidants 
Enzymatic antioxidants principally include SOD, catalase, glutathione peroxidases, 
and glutathione reductase. 
 
SOD. SODs catalyze the dismutation ·O2– to H2O2 and molecular oxygen (reaction 
1). There are three forms of SOD in mammalian systems: the copper-zinc (Cu, 
Zn-SOD), Mn-SOD, and extracellular SOD (EC-SOD) (Fridovich, 1997). SOD 
activity is decreased by homocysteine and increased by angiotensin II and 
hypertension. A key function of Cu, Zn-SOD is thought to protect against ·O2– 
induced inactivation of endothelial cell. 
2·O2– + 2H+ → H2O2 + O2     (1) 
 
Catalase and Peroxidases. Catalase directly decomposes H2O2 to water and 
molecular oxygen (reaction 2), whereas peroxidases eliminate H2O2 by using it to 
oxidize another substrate (reaction 3). 
2 H2O2 → 2H2O + O2     (2) 
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Substrate-H2 + H2O2 → substrate + 2 H2O  (3) 
 
Glutathione-Dependent Antioxidant Defences. Glutathione peroxidases 
cooperate with catalase in the removal of H2O2 in vivo by using reduced 
glutathione (GSH) to reduce H2O2 to H2O and oxidized glutathione (GSSG) 
(reaction 4). Glutathione peroxidases can also act on peroxides other than H2O2, 
e.g. tert.-BHP. Generally, they can catalyze GSH-dependent reduction of LOOH 
(e.g hydroperoxide formed from unsaturated fatty acid) to the corresponding 
alcohol (LOH) in the artery wall (reaction 5). Glutathione peroxidases operate in 
concert with glutathione reductase that catalyzes the reduction of GSSG at the 
expense of NADPH (reaction 6). 
H2O2 + 2GSH → 2H2O + GSSG   (4) 
LOOH + 2GSH → LOH + H2O + GSSG  (5) 
GSSG + NADPH + H+ → 2GSH + NADP+ (6) 
 
1.2.4.2 Non-enzyme Antioxidants 
Vitamin C (Ascorbate). Vitamin C is water soluble and ubiquitous in biological 
fluids. It enhances activity of enzymes through maintenance of the iron center in 
the active, ferrous state. Vitamin C is also a cofactor for several enzymes engaged 
in hydroxylation reactions. It provides the first line of defense against oxidative 
damage in human plasma. In addition to oxidant scavenging, ascorbate has a 
number of potentially protective activities related to atherosclerosis and 
cardiovascular disease. The mechanisms include the maintenance of eNOS activity, 
attenuation of cellular oxidative stress, inhibition of LDL oxidation. Ascorbate 
enhances eNOS through increasing cellular tetrahydrobiopterin. Ascorbate can 
also compete with ·O2– for reaction with NO. Therefore, ascorbate decreases ·O2– 
production and maintains NO synthesis by eNOS (Smith et al., 2002). 
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Vitamin E. Vitamin E is the major lipid-soluble antioxidant in lipoproteins and 
cells. It tends to localize in membranes and lipoproteins. In addition to scavenging 
peroxyl radicals, Vitamin E can also react with singlet oxygen and ONOO-. 
 
Coenzyme Q10. Coenzyme Q10 is found in all cell membranes, as well as 
lipoproteins. It also provides the first line of lipid-soluble antioxidant defense 
against human LDL lipid peroxidation. 
 
1.3 Questions 
The forgoing chapters showed that the effects of oxidative stress, especially of 
hydroperoxides on arterial functions are still controversial and the mechanisms 
involved not well understood. Therefore, the present study was performed, mainly 
with aortas from mice, to clarify the following questions: 
1) Which contractile effects exert H2O2 and tert.-butylhydroperoxide on aortic 
rings precontracted by KCl or phenylephrine? 
2) Which effects of the hydroperoxides are mediated by endothelium, and which 
effects are directly induced in smooth muscle? 
3) Which signalling pathways are involved in hydroperoxide-induced effects? For 
this aim, specific antagonists including PLA2-COX-TXA2 pathways, Ca2+ related 
pathways and voltage dependent K+ channels were used. 
4) Are there phenotypic effects in the contractile responses to hydroperoxides in 
animals lacking the gene for glutathione peroxidase-1? 
5) Are there phenotypic effects in the free radical generation stimulated by the 
hydroperoxides in animals lacking the gene for glutathione peroxidase-1? 
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2 Material 
2.1 Instruments 
Biophotometer, Eppendorf, Hamburg 
Clamp force amplifier, Hottinger, Darmstadt 
Digital pH-Meter Type 643-1, Schott, Hofheim 
Luminometer TD-20/20, Promega GmbH, Mannheim 
Mastercycler, Eppendorf, Hamburg 
Multi - Biolumat, LB 9505 C, Berthold, Bad wildbad 
Operation microscope with lighting device, Zeiss, Oberkochen 
Perfusion chamber for analysis of vessel wall mechanics, Physiological Institute, 
University Tuebingen 
Sensor of force transducers, Statham 
Spectrophotometer Genesys 6, Rochester, NY, USA 
Tripod pump ISM 853, Ismatec, Wertheim 
Two channels writer, ABB, Metrawatt 
Vortex, Bender&Hobein, Zürich, Switzerland 
Water bath heater, Colora, Lorch 
 
2.2 Chemicals and Reagents 
100% Acetic acid (CH3COOH), Detern 
Acetylcholine chloride (ACh), Sigma-Aldrich, Steinheim 
Albumin, bovine (BSA), Sigmal Chemical CO. USA 
4-Aminopyridine (4-AP), Sigma-Aldrich, Steinheim 
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2,2’-Azobis (2-Amidinopropane) hydrochloride (AAPH), Polysciences InC, 
Warrington, USA 
Bio-RAD-Reagenz Coomassie Brilliant Blue G250, Bio-Rad Labortatories GmbH, 
München 
Bupivacaine, Sigma-Aldrich, Steinheim 
tert.-Butylhydroperoxide (tert.-BHP), Merck, Darmstadt 
Calcium chloride dihydrate (CaCl2 2H2O), Roth, Karlsruhe 
Dantrolene, Sigma-Aldrich, Steinheim 
Diclofenac, Sigma-Aldrich, Steinheim 
Dimethyl sulfoxide (DMSO), Sigma-Aldrich, Steinheim 
Ethanol, Merck, Darmstadt 
Ethidiumbromid, Roth, Karlsruhe 
Ethylenediamine tetraacetic acid (EDTA), Sigma-Aldrich, Steinheim 
Fasudil hydrochloride, Biotrend Chemikalien GmbH, Köln 
Furegrelate sodium salt, Sigma-Aldrich, Steinheim 
α - D(+) - Glucose monohydrate, Roth, Karlsruhe 
Glybenclamide, Sigma-Aldrich, Steinheim 
L-Glutathione reduced, Sigma-Aldrich, Steinheim 
Glutathione Reductase, Sigma-Aldrich, Steinheim 
HEPES, Roth, Karlsruhe 
Hydrogen peroxide (H2O2) 30%, Sigma, Deisenhofen; Universitätsapotheke 
Indomethacin, Vaseline-Fabrik E. Wasserfuhr GmbH, Bonn 
Lucigenin (N, N’-Dimethyl-9, 9’-biacridiniumdinitrat), Serva, Heideberg 
Luminol (5-Amino-1, 2, 3, 4-tetrahydrophtalazin-1, 4-dion), Merck, Darmstadt 
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Magnesium sulfate (MgSO4 7H2O), Roth, Karlsruhe 
Meclofenamic, Sigma-Aldrich, Steinheim 
Methanol, Sigma-Aldrich, Steinheim 
ß-Nicotinamide adenine dinucleotide phosphate reduced form (ß-NADPH), 
Sigma-Aldrich, Steinheim 
Nifedipine, Sigma-Aldrich, Steinheim 
Nω-Nitro-L-Arginine methyl ester (L-NAME), Sigma-Aldrich, Steinheim 
2-Nitro-4-carboxyphenyl-N,N-diphenylcarbamate (NCDC), Sigma-Aldrich, 
Steinheim 
NucleoSpin®Tissue kit, Macherey-Nagel, Düren 
L-Phenylephrine HCl, Serva, Heidelberg 
Potassium chloride (KCl), Roth, Karlsruhe 
Potassium dihydrogen phosphate (KH2PO4), Roth, Karlsruhe 
Di-potassium hydrogen phosphate (K2HPO4), Merck, Darmstadt 
Procaine hydrochloride, Sigma-Aldrich, Steinheim 
Protein assay, Bio-Rad Laboratories GmbH, München 
Quinacrine dihydrochloride, Sigma-Aldrich, Steinheim 
Sodium chloride (NaCl), Merck, Darmstadt 
Sodium hydroxide (NaOH), Roth, Karlsruhe 
Sodium Di-hydrogen phosphate monohydrate (NaH2PO4 H2O), Roth, Karlsruhe 
TaKaRa, LA TaqTM, Japan 
Trizma base, Sigma-Aldrich, Steinheim 
Valsartan, Novartis Pharma, Wehr 
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2.3 Solution 
Physiological solution 
Normal-Tyrode solution pH 7.4 for 1 Liter 
NaCl 6.896 g 118.00 mM 
KCl 0.373 g 5.00 mM 
NaH2PO4 H2O 0.213 g 1.54 mM 
MgSO4 7H2O 0.293 g 1.19 mM 
CaCl2 2H2O 0.370 g 2.5 mM 
Hepes 2.383 g 10.00 mM 
Glucose 1.000 g 5.00 mM 
The solution with NaOH adjusted to pH 7.4 
 
30 mM KCl Tyrode solution 
30mM KCl Tyrode solution pH 7.4 for 1 Liter 
NaCl 5.452 g 93.00 mM 
KCl 2.236 g 30.00 mM 
NaH2PO4 H2O 0.213 g 1.54 mM 
MgSO4 7H2O 0.293 g 1.19 mM 
CaCl2 2H2O 0.220 g 1.50 mM 
Hepes 2.382 g 10.00 mM 
Glucose 1.000 g 5.00 mM 
The solution with NaOH adjusted to pH 7.4 
 
Phenylephrine-solution (PHE) 
Tyrode solution with phenylephrine [10-6 M] 
→ Using 10-2 M phenylephrine stock solution (dissolved in deionized water) 
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Solution for hydroperoxides 
H2O2-solution 
KCl enriched Tyrode-solution or phenylephrine-solution with H2O2 [10-5 M], 
[5 x 10-5 M], [1.25 x 10-4 M], [2.5 x 10-4 M], [5 x 10-4 M], [10-3 M]. 
→ Using 10-1 M, 1 M H2O2 stock solution (diluted in deionized water) 
 
tert.-BHP-solution 
KCl enriched Tyrode-solution or phenylephrine-solution with tert.-BHP [10-5 M], 
[5 x 10-5 M], [1.25 x 10-4 M], [2.5 x 10-4 M], [5 x 10-4 M], [10-3 M]. 
→ Using 10-1M, 1M tert.-BHP stock solution (diluted in deionized water) 
 
Solution for testing endothelial function 
ACh-solution 
KCl enriched Tyrode-solution with ACh [10-6 M], [5 x 10-6 M], [10-5 M], [10-4 M]. 
→ Using 10-2 M, 10-1 M ACh stock solution (dissolved in deionized water) 
 
L-NAME-solution 
KCl enriched Tyrode-solution with L-NAME [5 x 10-5 M]. 
→ Using 10-2 M L-NAME stock solution (dissolved in deionized water) 
 
Solution for Ca2+ channel inhibitors 
Dantrolene-solution (intracellular Ca2+ release inhibitor) 
KCl enriched Tyrode-solution with dantrolene [5 x 10-5 M]. 
→ Using 10-2 M dantrolene stock solution (dissolved in DMSO) 
18   Material 
 
Nifedipine-solution (selective L-type Ca2+ antagonist) 
KCl enriched Tyrode-solution with nifedipine [10-7 M]. 
→ Using 10-2 M nifedipine stock solution (dissolved in DMSO) 
 
Solution for Ca2+ sensitization inhibitor 
Fasudil-solution (Rho-kinase inhibitor) 
KCl enriched Tyrode-solution with fasudil [3 x 10-6 M]. 
→ Using 10-2 M fasudil stock solution (dissolved in deionized water) 
 
Solution for voltage-sensitive K+ channel inhibitor 
4-AP-solution (voltage-sensitive K+ channel inhibitor) 
KCl enriched Tyrode-solution or phenylephrine-solution with 4-AP [3 x 10-4 M]. 
→ Using 10-1 M 4-AP stock solution (dissolved in deionized water) 
 
Solution for PLA2-COX-TXA2 inhibitors 
Quinacrine-solution (PLA2 inhibitor) 
KCl enriched Tyrode-solution with quinacrine [10-5 M], [5 x 10-5 M]. 
→ Using 10-2 M quinacrine stock solution (dissolved in deionized water) 
 
Diclofenac-solution (COX inhibitor) 
KCl enriched Tyrode-solution with diclofenac [2 x 10-5 M]. 
→ Using 10-2 M diclofenac stock solution (dissolved in DMSO) 
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Indomethacin-solution (COX inhibitor) 
KCl enriched Tyrode-solution with indomethacin [2 x 10-4 M]. 
→ Using 10-1M indomethacin stock solution (dissolved in DMSO) 
 
Meclofenamic-solution (COX inhibitor) 
KCl enriched Tyrode-solution with meclofenamic [2 x 10-5 M]. 
→ Using 10-2 M miclofenamic stock solution (dissolved in DMSO) 
 
Bupivacaine-solution (TXA2 inhibitor) 
KCl enriched Tyrode-solution with bupivacaine [10-4 M]. 
→ Using 10-1 M bupivacaine stock solution (dissolved in ethanol) 
 
Furegrelate-solution (TXA2 inhibitor) 
KCl enriched Tyrode-solution with furegrelate [5 x 10-6 M]. 
→ Using 10-2 M furegrelate stock solution (dissolved in deionized water) 
 
Solution for PLC and AT1 receptor inhibitors 
NCDC-solution (PLC inhibitor) 
KCl enriched Tyrode-solution or phenylephrine-solution with NCDC [2 x 10-5 M]. 
→ Using 10-1 M NCDC stock solution (dissolved in ethanol) 
 
Valsartan (AT1 receptor inhibitor) 
KCl enriched Tyrode-solution with valsartan [10-5 M]. 
→ Using 10-1 M valsartan stock solution (dissolved in methanol) 
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Solution for DMSO, methanol, ethanol 
DMSO-solution 
KCl enriched Tyrode-solution with DMSO [2.8 x 10-3 M], [2.8 x 10-2 M]. 
→ Using 14.1 M DMSO stock solution 
 
Methanol-solution 
KCl enriched Tyrode-solution with methanol [2.47 x 10-3 M]. 
→ Using 24.7 M methanol stock solution 
 
Ethanol-solution 
KCl enriched Tyrode-solution or Phenylephrine-solution with ethanol 
[1.72 x 10-3 M], [1.72 x 10-2 M]. 
→ Using 17.2 M ethanol stock solution 
 
Solution for measuring chemiluminescence 
Lucigenin-solution 
Lucigenin was dissolved by DMSO [9.8 mM]. 
 
Luminol-solution 
Luminol was dissolved by DMSO [11.3 mM]. 
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PBS solution 
PBS solution pH 7.4 for 1 Liter 
Na2HPO4 2H2O 1.442 g 8.10 mM 
NaH2PO4 H2O 0.102 g 0.74 mM 
NaCl 8.182 g 140.00 mM 
KCl 0.201 g 2.70 mM 
The solution with NaOH adjusted to pH 7.4 
 
Solution for PCR 
Reaction mixture for PCR 
TaKaRa LA Taq TM (5 units/µl) 
10 x LA PCR TM Buffer (Mg2+ free) 
25 mM MgCl2 (final 2 mM) 
dNTP Mixture (2.5 mM each) 
Forward primer FinN (10 pM) 
Reverse primer R3N (10 pM) 
Reverse primer RpgkN (10 pM) 
Template 
Sterilized distilled water 
 
1 % Agarose gel 
1 g agarose in 100 ml 1 x TAE – Buffer 
 
50 x TAE – Buffer 1L, pH 8.5 
Trizma base  2.0 M 
CH3COOH  57.1 ml 
Na2EDTA 2H2O 0.1 M 
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Solution for GPx activity 
Potassium phosphate buffer 
100 ml KH2PO4 (1 M) was slowly added into 100 ml K2HPO4 (1 M) until pH 7 to 
get 1 M potassium phosphate buffer. When it is used, the buffer was diluted 1:10 
(0.1 M). 
 
NADPH - solution 
NADPH (1 mg/0.5 ml, 2.4 mM) was diluted by sterilized distilled water. 
 
Glutathione - solution 
Glutathione (3.1 mg/ml, 10 mM) was diluted by sterilized distilled water. 
 
Glutathione - reductase – solution 
10 µl Glutathione - reductase (120 U/ml) was diluted by 1 ml potassium phosphate 
butter with EDTA (50 µl 50 mM EDTA to 950 µl 0.1 M KPP buffer). 
 
EDTA – solution 
EDTA (29.2 mg/2ml, 50 mM) was diluted by sterilized distilled water. 
 
tert. - BHP solution 
tert. - BHP (10 µl/6 ml, 0.017 M) was diluted by sterilized distilled water. 
                                                                                                                 Methods 
 
23 
3 Methods 
3.1 Tissue Preparation and Organ Bath 
Wilde type mice (C57BL6) and GPx-1-/- mice at the age of 6 - 12 months were 
killed with carbon dioxide. The aorta was carefully dissected out, cleaned of 
adhering fat and connective tissues and cut into approximately 4 - 5 mm long 
segments under a dissecting microscope. The segment was equilibrated in an 
organ bath system for isometric tension recording (Blumenstein, 2004). The bath, 
which was maintained at 37 °C, contained physiological Tyrode solution. Two 
horizontally arranged stainless steel pins were passed through the lumen of the 
vascular cylinder. One pin was fixed to a micro-screw allowing the adaptation to a 
distant prestretching of the vessel ring, while the other one was vertically 
connected to a strain gauge for tension recording. The contraction was recorded by 
a force-displacement transducer. The solution in the organ bath was continuously 
perfused by approx 5 ml/min. To examine endothelium independent responses, 
some aorta rings was mechanically removed by rubbing the internal surface of the 
ring with a fine wooden stick, and successful removal of endothelium was verified 
by the absence of contraction response to L-NAME [5 x 10-5 M] (E+: the aorta 
with endothelium; E-: the aorta without endothelium). 
 
3.2 Reactivity Experiments 
After 30 min of equilibration, the segment was precontracted by 30 mM KCl 
enriched Tyrode solution or PHE [1 µM] until a stable contraction was achieved. 
To assess the contractile response to H2O2 and tert.-BHP, the segment was then 
exposed to a single concentration of H2O2 [10-5-10-3 M] or tert.-BHP [10-5-10-3 M] 
applied in the corresponding stimulation solution. While continuously perfused by 
the hydroperoxide containing solution, 15 - 20 min reaction time with the aorta 
was allowed, followed by a thorough wash with Tyrode solution. The maximum 
contraction of H2O2 and tert.-BHP was expressed as a percentage of the  
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precontraction. Fig 1 showes the experimental procedure of the contractile 
response to the hydroperoxide. 
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Fig 1 Typical tracing showing the response to hydroperoxides (H2O2 and tert.-BHP) in 
the mouse aorta. The contraction was expressed in mN. Maximum contractile response to 
H2O2 and tert.-BHP was expressed as a percentage of KCl- or PHE- precontraction. 
 
The modulation of the responses to H2O2 and tert.-BHP by the antagonists and 
agonist was assessed. The agonist and antagonists included: ACh 
(endothelium-dependent agonist), L-NAME (NOS inhibitor), quinacrine (PLA2 
synthase inhibitor), diclofenac (COX inhibitor), indomethacin (COX inhibitor), 
meclofenamic (COX inhibitor), bupivacaine (TXA2 synthase inhibitor), 
furegrelate (TXA2 synthase inhibitor), NCDC (PLC inhibitor), nifedipine (L-type 
Ca2+ channel antagonist), dantrolene (intracellular Ca2+ release inhibitor), fasudil 
(Rho-kinase inhibitor) 4-AP (voltage-sensitive K+ channel inhibitor), valsartan 
(Angiotensin II AT1 receptor antagonist). The concentrations of the different 
antagonists and agonist used in the experiments referred to the related papers and 
the procedure of reactivity experiment for each drug will be shown in the result 
part. 
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3.3 PCR for Genotype Determination of Glutathione 
Peroxidase-1 
Mice homozygous for disruption of the GPx-1 gene were kindly provided by 
Professor K.J. Lackner (Mainz University) and subsequently bred at our institution. 
In these mice, the gene of GPx-1 was inactivated by insertion of a neomycin 
resistance gene (NEO) cassette into an EcoRI site located in exon 2 of the GPx-1 
gene, which was then inserted into embryonic stem cells (Ursini et al., 1995). 
 
Genotype determination: DNA was obtained by extraction from the mouse ear by 
using NucleoSpin® Tissue kit as described. To identify the WT GPx-1 gene, we 
used the forward primer FinN (5'-GTTTCCCGTGCAATCAGTTCG-3') and the 
reverse primer R3N (5'-TCGGACGTACTTGAG-GGAAT-3') to amplify a 293bp 
fragment. To detect GPx-1-/- mice, we used FinN and RpgkN 
(5'-CATTTGTCACGTCCTGCAC-3') as the reverse primer to amplify a 509bp 
fragment in the NEO insert. Reaction products were analyzed by electrophoresis 
on a 1% agarose gel. WT mice were identified by an exclusive 293bp PCR 
product, and GPx-1-/- mice were identified by an exclusive 509bp product. 
 
PCR for genotype 
determination:
WT mice were identified 
by a 293bp PCR fragment, 
whereas GPx-1-/- mice 
were identified by a 509bp 
PCR product.
DNA-
ladder GPx1-/- WT
509bp
293bp
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3.4 Measurement of Glutathione Peroxidase Activity 
3.4.1 Principle of the Procedure 
In this assay tert.–BHP is used, and glutathione reductase and β-NADPH 
(β-nicotinamide adenine dinucleotide phosphate, reduced) are included in the 
reaction mixture. The formation of GSSG catalyzed by GPx is coupled to the 
recycling of GSSG back to GSH using GSSG-R. NADPH is oxidized to NADP+. 
The change in A366 due to NADPH oxidation is monitored and is indicative of 
GPx activity. Since all other reagents are provided in excess, the amount of GPx in 
the test sample is the rate-limiting factor and the rate of decrease in the A366 is 
directly proportional to the GPx activity in the sample. The over-all 2 step reaction 
is: 
 
GPx
NADP+
ROOH + 2GSH
NADPH
GSSG -R
ROH + GSSG 2GSH
 
3.4.2 Glutathione Peroxidase Assay 
Using tissues from WT and GPx-1-/- mice, livers and aortas were homogenized in 
2-3 volumes of KPP buffer and supernatant from the top of the tube (5000 RPM, 
10 min) was taken for the assay. Blood was collected using heparin as the 
anticoagulant and RBC was spun down by centrifugation at 3000 rpm for 10min at 
4°C. RBC was added into two volumes of DI (deionized) water to get hemolysate 
by complete lysis. The enzyme reaction was conducted in a buffer containing 
potassium phosphate (100 mM), glutathion-reductase (120 U/ml), glutathione 
(10 mM), NADPH (2.4 mM), EDTA (0.5 mM) and tert.-BHP (0.017 mM) at 
37 °C, and the rate of decrease in absorption of NADPH at 366 nm was followed. 
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Activities were expressed as units per mg of protein. The protein concentrations of 
the homogenate were also determined (Biorad Assay). 
 
The calculation 
Specific activity (mU/mg) =
394 x (VTotal/VProbe) x (∆ E/min)
protein concentration of sample (mg/ml)
VTotlal = the total volume in the tube
VProbe = the volume of the sample added 
∆ E /min = the rate of decrease in A366/ the time of the rate of decrease in A366
 
Activity of GPx  
(mU/mg) 
WT mouse n GPx-1-/- mouse n 
Aorta 4.57 ± 1.17 7 1.06 ± 0.14 8 
Liver 27.03 ± 6.10 7 8.59 ± 6.20 9 
Blood 6.92 ± 0.70 6 4.82 ± 0.90 10 
Table 1 The difference of GPx activity in different tissues between WT and GPx-1-/-. 
Results (Mean ± SD) were expressed in mU/mg, n = the number of the mice. 
 
3.5 Chemiluminescence (CL) Assays 
The theoretical considerations of lucigenin- and luminol-enhanced 
chemiluminescence: Lucigenin has been widely used as an indicator of ·O2– 
production. In 1991, it was introduced as a tool to measure ·O2– in vascular tissue 
by Wolin’s group (Omar et al., 1991). Lucigenin carries a positive ionic charge 
and it is generally thought to be relatively membrane impermeant. Therefore 
lucigenin is respond to reactive oxygen species, particularly superoxide anion 
(·O2–), in the extracellular space. In contrast, the uncharged luminol molecule is 
membrane permeant and can react (in the form of luminol or as a univalently 
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oxidized luminol radical) with a variety of reactive oxygen species, including ·O2–, 
OH•, and H2O2 at higher concentrations (above 0.5 mM H2O2). So luminol reflects 
extracellular as well as intracellular ROS production. 
 
The procedure was carried out with Luminometer TD-20/20. For wild type and 
GPx-1-/- mouse aorta, one segment of ≈ 8 mm was used in each assay. The 
segment was weighted. The vessels were then placed in a plastic cuvette 
containing physiological Tyrode solution, 5 µl luminol [11.3 mM] or 5 µl 
lucigenin [9.8 mM] and hydroperoxides [0.01-1 mM] in a total volume of 500 µl. 
CL was measured in the luminometer for 10 min. The indicated relative light units 
(RLU), which are relative measure of the integrated counts of photons, were 
related to the weight of the aortic samples. These values were compared to the 
measurements without hydroperoxides and without tissues, respectively. 
 
AAPH is a water-soluble azo compound which is used extensively as a free radical 
generator, often in the study of lipid peroxidation and the characterization of 
antioxidants (Noguchi et al., 1998;Rice-Evans & Miller, 1994). The half-life of 
AAPH is about 175 hours (37°C at neutral pH), making the rate of free radical 
generation essentially constant during the first several hours in solution (Niki, 
1990). To estimate antioxidative properties of the different drugs, we used the 
AAPH method. In these experiments, PBS, 5 µl luminol [11.3 mM] and 10 µl 
AAPH [0.5 M] were added into a plastic cuvette, and CL was measured in 
multi-biolumat for 20 min until the production of ROS induced by AAPH was 
stable. Then the drug was added into the plastic cuvette (total volume = 500 µl) 
and CL was measured for another 40 min. 
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3.6 Statistical analysis  
Results are expressed as Mean±SD. For statistical comparison, the student’s t-test 
was used to determine significant differences between means. P value less than 
0.05 was considered significant. More than three mice were used in each set of 
experiments.
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4 Results 
4.1 Effects of Hydroperoxides on KCl- and PHE-induced 
Contraction in the Aorta of WT Mouse with Endothelium 
In KCl [30 mM]-precontracted mouse aorta, H2O2 caused concentration-dependent 
contractile response at the concentrations of 0.01-0.5 mM, but produced relaxation 
at the concentration of 1 mM. The maximum stimulation was reached at 0.25 mM 
(159.0 ± 11.0 % of the contraction induced by 30 mM KCl, Fig 1a). As shown in 
Fig 1b, tert.-BHP [0.01-0.25 mM] caused similarly concentration-dependent 
increase in tension, reached a peak at 0.125 mM (149.2 ± 26.5 % of the response 
to 30 mM KCl), and also caused relaxation at high concentrations [0.5-1 mM]. 
 
 
 
 
 
 
 
 
 
 
 
Fig 1a Concentration-response curve of H2O2 in 30 mM KCl-precontracted WT mouse 
aorta with endothelium. Results (Mean ± SD) were from 6 - 8 mice. The results were 
expressed as percentages of the contraction with 30 mM KCl. The average 
KCl-precontraction was 6.6±3.3 mN. Each concentration of H2O2 has its own control 
(KCl-precontraction). Absolute data (mN) was used for comparison. *P<0.05. 
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Fig 1b Concentration-response curve of tert.-BHP in 30 mM KCl-precontracted WT 
mouse aorta with endothelium. Results (Mean ± SD) were from 6 - 20 mice. The results 
were expressed as percentages of the contraction with 30 mM KCl. The average 
KCl-precontraction was 4.8±2.9 mN. Each concentration of tert.-BHP has its own control 
(KCl-precontraction). Absolute data (mN) was used for comparison. *P<0.05. 
 
Following contraction to PHE [1 µM], H2O2 and tert.-BHP increased contraction 
at the concentrations of 0.01-0.125 mM respectively. The maximum responses to 
H2O2 and tert.-BHP were both at 0.05 mM (144.8 ± 15.6 % and 131.7 ± 15.5 % of 
the contraction induced by 1 µM PHE, respectively, Fig 2a, 2b). 
 
For further investigation on hydroperoxide-enhanced contraction mechanisms, we 
selected 0.05 mM of H2O2 and tert.-BHP. These results indicated that H2O2 and 
tert.-BHP increased contraction induced by KCl and PHE in the mouse aorta, 
which was dose dependent in a range of lower concentrations. 
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Fig 2a Concentration-response curve of H2O2 in 1 µM PHE-precontracted WT mouse 
aorta with endothelium. Results (Mean ± SD) were from 5 - 6 mice. The results were 
expressed as percentages of the contraction with 1 µM PHE. The average contraction of 
1 µM PHE was 7.9±3.7 mN. Each concentration of H2O2 has its own control 
(PHE-precontraction). Absolute data (mN) was used for comparison. *P<0.05. 
 
 
 
 
 
 
 
 
 
Fig 2b Concentration-response curve of tert.-BHP in 1 µM PHE-precontracted WT 
mouse aorta with endothelium. Results (Mean ± SD) were from 5 - 6 mice. The results 
were expressed as percentages of the contraction with 1 µM PHE. The average 
contraction of 1 µM PHE was 10.7±5.4 mN. Each concentration of tert.-BHP has its own 
control (PHE-precontraction). Absolute data (mN) was used for comparison. *P<0.05. 
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4.2 Effects of Endothelium on Hydroperoxide-enhanced 
Contraction in WT Mouse Aorta 
4.2.1 Effects of ACh on Hydroperoxide Stimulated Contraction in 
Intact Mouse Aorta 
Concerning the role of endothelium in the response to hydroperoxides, ACh was 
used in this study. The experimental procedure: Following the equilibration of 
30 min, the segment was contracted by 30 mM KCl to reach a plateau level. After 
the first contraction was obtained, ACh [0.1 mM] was added into the KCl-Tyrode 
solution. 10-15 min reaction time was allowed, followed by a thorough wash with 
Tyrode solution. The maximum response to ACh was expressed as a percentage of 
30 mM KCl-precontraction. To assess the effect of ACh on H2O2- and 
tert.-BHP-induced contraction, the segment was additionally exposed to ACh 
[0.1 mM] with H2O2 [0.05 mM] or tert.-BHP [0.05 mM] when the 
hydroperoxide-induced contraction had reached a plateau. The maximum response 
to ACh with H2O2, tert.-BHP was also expressed as a percentage of 30 mM 
KCl-precontraction. Fig 3a showes the experimental procedure of the effect of 
ACh on hydroperoxide-induced contraction. 
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Fig 3a Typical model showing the effect of ACh on KCl-induced contraction and 
on hydroperoxide-stimulated contraction (H2O2 and tert.-BHP). S.C means 
standard contraction. The contraction was expressed in mN. 
 
ACh [0.1 mM] relaxed contraction induced by 30 mM KCl in mouse aorta with 
intact endothelium. The relaxation of ACh amounted to 77.7 ± 9.8 % of 
KCl-precontraction (Fig 3b). Then we investigated the effect of ACh on 
hydroperoxide-enhanced contraction. As shown in Fig 3c, ACh [0.1 mM] 
significantly decreased the contraction induced by both hydroperoxides. The 
response to ACh in H2O2-increased contraction amounted to 92.6 ± 5.2 % of 
H2O2-enhanced contraction (p<0.05, n=4). For tert.-BHP, the relaxation of ACh 
amounted to 86.2 ± 0.8 % of tert.-BHP-induced contraction (p<0.05, n=3). 
 
 
 
 
 
 
 
 
 
 
Fig 3b The effect of ACh (0.1 mM) on KCl-precontraction in WT mouse aorta with 
endothelium. Results (Mean ± SD) were from 5 mice. The results were expressed as 
percentages of the contraction with 30 mM KCl. The contraction of control was 
3.4±0.5 mN and the response to ACh was 2.6±0.6 mN. Absolute data (mN) was used for 
comparison. *P<0.05. 
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Fig 3c The effect of 0.1 mM ACh on the hydroperoxide-enhanced contraction in WT 
mouse aorta with endothelium. Results (Mean ± SD) were from 3 - 4 mice. The results 
were expressed as percentages of the contraction with 30 mM KCl. *P<0.05 compared 
with control. 
 
4.2.2 Effects of L-NAME on Hydroperoxide-enhanced Contraction in 
Intact Mouse Aorta 
To study the role of NO in the response to hydroperoxides, NOS inhibitor 
(L-NAME) was used in KCl-precontraction and hydroperoxide-enhanced 
contraction. The experimental procedure for application of L-NAME was the same 
as ACh. L-NAME [0.05 mM] significantly increased 30 mM KCl-induced 
contraction (Fig 4a). The response to 0.05 mM L-NAME amounted to 
117.5 ± 6.7 % (p<0.05, n = 5) of KCl-precontraction. L-NAME [0.05 mM] 
significantly increased H2O2- and tert.-BHP-enhanced contraction in the mouse 
aorta (Fig 4b). 
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Fig 4a The effect of L-NAME on 30 mM KCl precontraction in WT mouse aorta with 
endothelium. Results (Mean ± SD) were from 5 mice. The results were expressed as 
percentages of the contraction with 30 mM KCl. The contraction of control was 
6.2±2.9 mN and the response of L-NAME was 7.4±3.7 mN. Absolute data (mN) was 
used for comparison. *P<0.05 compared with control. 
 
 
 
 
 
 
 
 
 
 
Fig 4b The effect of 0.05 mM L-NAME on hydroperoxide-enhanced contraction in WT 
mouse aorta with endothelium. Results (Mean ± SD) were from 7 - 9 mice. The results 
were expressed as percentages of the contraction with 30 mM KCl. *P<0.05 compared 
with control. 
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4.2.3 Endothelium-independent Contraction to H2O2 and tert.-BHP 
As shown in Fig 5a, L-NAME increased 30 mM KCl precontraction in intact WT 
mouse aorta, but not in preparations of denuded endothelium (E-). The results 
confirmed the successful removal of endothelium. 
 
In E- mouse aorta, the contractile response to tert.-BHP [0.05 mM] amounted to 
160.2 ± 18.9 % of KCl precontraction, which was significantly bigger than in E+ 
mouse aorta (126.0 ± 15.8 %). Removal of endothelium also increased the 
contractile response to H2O2 (the contractile response to H2O2 in E-: 
166.0 ± 19.5 %, the contractile response to H2O2 in E+: 125.7 ± 13.2 %, Fig 5b). 
The results indicated that intact endothelium inhibited the tone of the artery 
induced by both hydroperoxides. 
 
 
 
 
 
 
 
 
 
Fig 5a The different effect of L-NAME (0.05 mM) on 30 mM KCl-induced contraction 
in WT mouse aorta with intact- (E+) and denuded- (E-) endothelium. Results 
(Mean ± SD) were from 5 mice. The results were expressed as percentages of the 
contraction with 30 mM KCl. In E+ group, the contraction of control was 6.2±2.9 mN 
and the response to L-NAME was 7.4±3.7 mM. In E- group, the contraction of control 
was 3.99±0.8 mN and the response to L-NAME was 3.97±1.1 mN. Absolute data (mN) 
was used for comparison. *P<0.05 compared with control. 
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Fig 5b The difference of hydroperoxide-enhanced contraction in WT mouse aorta with 
intact- (E+) and denuded- (E-) endothelium. Results (Mean ± SD) were from 6 mice. The 
results were expressed as percentages of the contraction with 30 mM KCl. *P<0.05 
compared with the response to hydroperoxides with endothelium. 
 
4.3 Pharmacological Characterization of the Effects of 
Hydroperoxides on the Contraction in WT Mouse Aorta 
4.3.1 Effects of Ca2+ Channel and Sensitization Inhibitors 
To study the sources of Ca2+ involved in the hydroperoxide-enhanced contraction, 
experiments were performed with intracellular Ca2+ release inhibitor (dantrolene), 
selective L-type Ca2+ antagonist (nifedipine) and Ca2+ sensitization inhibitor 
(fasudil). The concentrations of dantrolene, nifedipine and fasudil used in this 
study referred to Du W (Du et al., 2005), Bergdahl et al (Bergdahl et al., 2005) 
and Shimomura et al (Shimomura et al., 2004), respectively. Fig 6a showed the 
experimental procedure to determine the effects of these drugs on 
hydroperoxide-enhanced contraction. Firstly, the contractile response to 
hydroperoxide (0.05 mM H2O2 or tert.-BHP) was tested, followed by a wash with 
Tyrode solution. The maximum contraction of hydroperoxides was expressed as a 
percentage of 30 mM KCl-precontraction. Then, the aorta was exposed to one of 
the inhibitors with KCl since these drugs inhibited KCl precontraction (Fig 6b). 
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When the contraction was obtained, 0.05 mM hydroperoxide was added. The 
contractile response to hydroperoxides was expressed as a percentage of the 
contraction of KCl with the inhibitor. Since dantrolene and nifedipine were 
initially dissolved in dimethyl sulfoxide (DMSO) to prepare the stock solution, the 
effect of the same amount of DMSO on KCl precontraction and 
hydroperoxide-enhanced contraction was also studied (Fig 6c). 
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Fig 6a Typical model showing the effects of the Ca2+ channel and sensitization inhibitors 
on hydroperoxide-enhanced contraction. S.C means standard contraction. The contraction 
was expressed in mN. 
 
As shown in Fig 6b, dantrolene (50 µM, intracellular Ca2+ release inhibitor), 
nifedipine (0.1 µM, selective L-type calcium antagonist) and fasudil (3 µM, 
Rho-kinase inhibitor) significantly reduced the contraction induced by 30 mM KCl, 
while DMSO (0.028 M) had no effect on KCl-precontraction and 
hydroperoxide-enhanced contraction (Fig 6c). 
 
In the presence of dantrolene, the contractile responses to H2O2 and tert.-BHP 
were significantly decreased. Nifedipine also reduced the contraction of H2O2
40   Results 
 
tert.-BHP. Furthermore, fasudil significantly inhibited the contractile responses to 
H2O2 and tert.-BHP (Fig 6d). However, since these drugs are also to inhibit 
KCl-induced contraction, their specificity has to be questioned. 
 
 
 
 
 
 
 
 
 
Fig 6b The effects of the Ca2+ channel and sensitization inhibitors on KCl-induced 
contraction. Results (Mean ± SD) were from 3 - 4 mice. The results were expressed as 
percentages of the contraction with 30 mM KCl. For dantrolene, the contraction of 
control was 7.2±1.6 mN and the response to dantrolene was 5.0±1.2 mN. For nifedipine, 
the contraction of control was 7.1±1.9 mN and the response to nifedipine was 
5.5±1.8 mN. For fasudil, the contraction of control was 10.4±2.4 mN and the response to 
fasudil was 7.5±2.5 mN. Absolute data (mN) was used for comparison. *P<0.05, 
**P<0.01 compared with control. 
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Fig 6c The effects of DMSO on KCl-induced and hydroperoxide-enhanced contraction. 
Results (Mean ± SD) were from 4 - 5 mice. The results were expressed as percentages of 
the contraction with 30 mM KCl. 
 
 
 
 
 
 
 
 
 
Fig 6d Effects of the Ca2+ channel and sensitization inhibitors on 
hydroperoxide-enhanced contraction. Results (Mean ± SD) were from 4 - 5 mice. The 
results were expressed as percentages of the contraction induced by KCl (Control group) 
or by KCl + one of the inhibitors (the inhibitor group). *P<0.05, **P<0.01 compared 
with control. 
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4.3.2 Effects of Voltage-sensitive K+ Channel Inhibitor on PHE-induced 
and Hydroperoxide-enhanced Contraction 
In order to characterize the involvement of the voltage-sensitive K+ channel in 
hydroperoxide-enhanced contraction, the experiments were performed with 
voltage-sensitive K+ channel inhibitor 4-AP. Since depolarisation by 30 mM KCl 
influences K+ channels very strongly, stimulation with 1 µM PHE was used in 
these experiments. The concentration of 4-AP used in the experiments referred to 
Plane et al (Plane et al., 2005). Fig 7a showed the experimental procedure: firstly, 
the contractile response to the hydroperoxide (0.05 mM H2O2 or tert.-BHP) was 
tested. The maximum contraction of hydroperoxides was expressed as a 
percentage of the PHE-precontraction. Then the segment was exposed to 4-AP 
when the precontraction had reached a plateau. The contractile response to 4-AP 
was expressed as a percentage of the precontraction. When the contraction of 
4-AP was stable, 0.05 mM hydroperoxide (H2O2 or tert.-BHP) was added. The 
response to the hydroperoxide was expressed as a percentage of PHE with 4-AP. 
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Fig 7a Typical model showing the effect of 4-AP on the hydroperoxide-enhanced 
contraction (H2O2 and tert.-BHP). S.C means standard contraction. The contraction was 
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expressed in mN. The response to the hydroperoxide in control group was expressed as a 
percentage of the contraction induced by PHE (1 µM). In the presence of 4-AP, the 
response to H2O2 and tert.-BHP was expressed as a percentage of the contraction induced 
by PHE with 4-AP. 
 
The voltage sensitive K+ channel inhibitor (0.3 mM 4-AP) significantly increased 
the contraction induced by 1 µM PHE (Fig 7b). In the following experiments, we 
examined the effects of 4-AP on the contractile response to hydroperoxides 
(0.05 mM H2O2 and tert.-BHP). 4-AP showed a greater inhibition of the 
hydroperoxide-enhanced contraction in WT mouse aorta (Fig 7c). In control group, 
the contraction of H2O2 and tert.-BHP amounted to 148.5 ± 14.6 % and 
156.5 ± 14.4 % of PHE-precontraction. In the presence of 4-AP, the response to 
H2O2 and tert.-BHP amounted to 101.0 ± 7.0 % and 108.3 ± 8.2 % of 
PHE-precontraction with 4-AP. 
 
 
 
 
 
 
 
 
 
Fig 7b Effects of the voltage sensitive K+ channel inhibitor (0.3 mM 4-AP) on PHE 
precontraction. Results (Mean ± SD) were from 8 WT mice. The results were expressed 
as percentages of the contraction with 1 µM PHE. The contraction of control was 
7.2±1.5 mN and the response to 4-AP was 9.0±2.2 mN. Absolute data (mN) was used for 
comparison. *P<0.05 compared with control. 
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Fig 7c Effects of the voltage sensitive K+ channel inhibitor (0.3 mM 4-AP) on 
hydroperoxide-enhanced contraction. Results (Means ± SD) were from 4 WT mice. The 
results were expressed as percentages of the contraction induced by 1 µM PHE (Control 
group) or by PHE + 4AP (4-AP group). *P<0.05, **P<0.01 compared with control. 
 
4.3.3 Effects of PLA2-COX-TXA2 Inhibitors on 
Hydroperoxide-enhanced Contraction 
To assess the effects of PLA2-COX-TXA2 inhibitors, PLA2 inhibitor (quinacrine), 
COX inhibitors (diclofenac, indomethacin, meclofenamic) and TXA2 inhibitors 
(bupivacaine, furegrelate) were used in the experiments. The experimental 
procedure was shown in Fig 8a. Firstly, the contractile response to the 
hydroperoxide (0.05 mM H2O2 or tert.-BHP) was tested, followed by a wash with 
Tyrode solution. The response to hydroperoxides was expressed as a percentage of 
the contraction induced by KCl (30 mM). Then, some aortas were exposed to one 
of the inhibitors together with KCl solution. When the contraction was obtained, 
0.05 mM hydroperoxide was added. The contraction of hydroperoxides was 
expressed as a percentage of the contraction induced by KCl with the inhibitor. 
The effect of the same amount of DMSO and ethanol on KCl precontraction and 
hydroperoxide-enhanced contraction was also studied since indomethacin, 
diclofenac and meclofenamic were initially dissolved in DMSO, and bupivacaine 
was dissolved in ethanol to prepare the stock solution. 
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Fig 8a Typical model showing the effects of PLA2-COX-TXA2 inhibitors on 
hydroperoxide-enhanced contraction (H2O2 and tert.-BHP). S.C means standard 
contraction. The contraction was expressed in mN. The response to the hydroperoxide in 
the control group was expressed as a percentage of 30 mM KCl-precontraction. In the 
presence of the inhibitor, the response to H2O2 and tert.-BHP was expressed as a 
percentage of the contraction induced by KCl with the inhibitor. 
 
4.3.3.1 Effects of PLA2 Inhibitor (quinacrine) 
As shown in Fig 8b, 10 µM quinacrine had no effect on KCl precontraction, while 
50 µM quinacrine significantly decreased the contraction induced by KCl. The 
concentrations of quinacrine used in the experiments referred to Tiritilli et al 
(Tiritilli et al., 2004). In the experimental procedure, the hydroperoxide was added 
when the contraction of KCl with the inhibitor was stable since the inhibitor at 
higher concentration had a decreasing effect on KCl precontraction. Since 10 µM 
quinacrine was not effective in tert.-BHP group, 50 µM quinacrine was used. 
Furthermore, we observed that quinacrine significantly abolished the contractile 
response to H2O2 and tert.-BHP (Fig 8c, 8d). The results suggested that PLA2 was 
involved in the contractile response to both hydroperoxides. 
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Fig 8b Effects of quinacrine on KCl precontraction. Results (Mean ± SD) were from 3 - 5 
WT mice. The results were expressed as percentages of 30 mM KCl-precontraction. For 
10 µM quinacrine group, the contraction of control was 5.0±2.4 mN and the response to 
quinacrine was 4.9±2.3 mN. For 50 µM quinacrine group, the contraction of control was 
6.0±3.2 mN and the response to quinacrine was 4.4±2.1 mN. Absolute data (mN) was 
used for comparison. *P<0.05. compared with control. 
 
 
 
 
 
 
 
 
Fig 8c Effects of quinacrine on H2O2-enhanced contraction. Results (Mean ± SD) were 
from 5 WT mice. The results were expressed as percentages of the contraction induced 
by 30 mM KCl (Control group) or by KCl + quinacrine (quinacrine group). *P<0.05 
compared with control. 
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Fig 8d Effects of quinacrine on tert.-BHP-enhanced contraction. Results (Means ± SD) 
were from 3 WT mice. The results were expressed as percentages of the contraction 
induced by 30 mM KCl (Control group) or by KCl + quinacrine (quinacrine group). 
*P<0.05 compared with control. 
 
4.3.3.2 Effects of COX Inhibitors (diclofenac, indomethacin, meclofenamic) 
The concentrations of diclofenac, indomethacin and meclofenamic used in the 
experiments referred to Gao et al (Gao et al., 2003), Tiritilli et al (Tiritilli et al., 
2004) and Climent et al (Climent et al., 2005). Diclofenac (20 µM) and 
meclofenamic (20 µM) had no effects on the contraction induced by KCl, but 
indomethacin (200 µM) significantly abolished the contractile response to KCl 
(Fig 9a). Moreover, Fig 9b, 9c showed that diclofenac, meclofenamic and 
indomethacin significantly inhibited the contraction of hydroperoxides (H2O2 and 
tert.-BHP), indicating that COX was involved in the hydroperoxide-enhanced 
contraction. The same amount of DMSO had no effects on KCl-precontraction and 
hydroperoxide-enhanced contraction (data not shown). 
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Fig 9a Effects of COX inhibitors (diclofenac, meclofenamic and indomethacin) on KCl 
precontraction. Results (Mean ± SD) were from 3 - 4 WT mice. The results were 
expressed as percentages of 30 mM KCl-precontraction. For diclofenac, the contraction 
of control was 7.8±1.3 mN and the response to diclofenac was 7.9±1.5 mN. For 
meclofenamic, the contraction of control was 3.8±1.5 mN and the response to 
meclofenamic was 3.6±1.3 mN. For indomethacin, the contraction of control was 
9.6±3.4 mN and the response to indomethacin was 4.9±2.6 mN. Absolute data (mN) was 
used for comparison.*P<0.05 compared with control. 
 
 
 
 
 
 
 
 
 
Fig 9b Effects of COX inhibitors (diclofenac, meclofenamic and indomethacin) on 
H2O2-enhanced contraction. Results (Mean ± SD) were from 3 - 4 WT mice. The results 
were expressed as percentages of the contraction induced by 30 mM KCl (Control group) 
or by KCl + one of the inhibitors (the inhibitor group).*P<0.05, **P<0.01 compared with 
control. 
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Fig 9c Effects of COX inhibitors (diclofenac, meclofenamic and indomethacin) on 
tert.-BHP-enhanced contraction. Results (Mean ± SD) were from 4 - 5 WT mice. The 
results were expressed as percentages of the contraction induced by 30 mM KCl (Control 
group) or by KCl + one of the inhibitors (the inhibitor group). *P<0.05, **P<0.01 
compared with control. 
 
4.3.3.3 Effects of TXA2 Inhibitors (bupivacaine, furegrelate) 
The concentrations of bupivacaine and furegrelate used in the experiments referred 
to Hahnenkamp et al (Hahnenkamp et al., 2004) and Hernanz et al (Hernanz et al., 
2003). As shown in Fig 10a, bupivacaine (0.1 mM) had no effect on 30 mM 
KCl-precontraction, but significantly increased the contraction induced by 1 µM 
PHE. In KCl- and PHE-precontraction, bupivacaine abolished the hydroperoxide 
(H2O2 or tert.-BHP) enhanced contraction (Fig 10b, 10c). Since bupivacaine was 
dissolved by ethanol, the effect of ethanol on contractions was also considered. 
The same concentration of ethanol had no effect on KCl-, PHE-precontraction and 
hydroperoxide-enhanced contraction (data not shown). 
 
 
 
 
80
90
100
110
120
130
140
150
160
Control Diclofenac 20µM Meclofenamic
20µM
Indomethacin
200µM
tert. -BHP 0.05mM
%
 
C
o
n
tr
a
ct
io
n
**
*
**
50   Results 
 
 
 
 
 
 
 
 
 
Fig 10a Effects of bupivacaine on KCl- and PHE-precontraction. Results (Mean ± SD) 
were from 5 - 6 WT mice. In KCl group, the results were expressed as percentages of 
30 mM KCl-precontraction. The contraction of control was 6.4±0.9 mN and the response 
to bupivacaine was 5.9±1.0 mN. In PHE group, the results were expressed as percentages 
of 1 µM PHE-induced contraction. The contraction of control was 8.9±0.4 mN and the 
response to bupivacaine was 13.9±1.6 mN. Absolute data (mN) was used for comparison. 
*P<0.05 compared with control. 
 
 
 
 
 
 
 
 
 
Fig 10b Effects of bupivacaine on H2O2-enhanced contraction. Results (Mean ± SD) 
were from 3 WT mice. The results were expressed as percentages of the contraction 
induced by 30 mM KCl and PHE (Control group) or by KCl (PHE) + bupivacaine 
(bupivacaine group). *P<0.05 compared with control. 
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Fig 10c Effects of bupivacaine on tert.-BHP-enhanced contraction. Results (Mean ± SD) 
were from 3 WT mice. The results were expressed as percentages of the contraction 
induced by 30 mM KCl and PHE (Control group) or by KCl (PHE) + bupivacaine 
(bupivacaine group). *P<0.05 compared with control. 
 
The effects of another TXA2 inhibitor (furegrelate) were also analysed. 5 µM 
furegrelate abolished the contractile response to H2O2. Furegrelate also decreased 
contraction by tert.-BHP, but due to large variation this effect did not reach 
significance (Fig 11a). In contrast, furegrelate did not significantly affect the 
contraction induced by 30 mM KCl (Fig 11b). 
 
 
 
 
 
 
 
Fig 11a Effects of TXA2 inhibitor (5 µM furegrelate) on the hydroperoxide-enhanced 
contraction. Results (Mean ± SD) were from 3 - 7 WT mice. The results were expressed 
as percentages of the contraction induced by 30 mM KCl (Control group) or by 
KCl + furegrelate (furegrelate group). *P<0.05 compared with control. 
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Fig 11b Effects of TXA2 inhibitor (5 µM furegrelate) on KCl-induced contraction. 
Results (Means ± SD) were from 6 WT mice. The results were expressed as percentages 
of 30 mM KCl-induced contraction. The contraction of control was 2.9±0.9 mN and the 
response to furegrelate was 2.6±1.1 mN. 
 
4.3.4 Effects of PLC Inhibitor and AT1 Receptor Antagonist 
4.3.4.1 Effects of PLC Inhibitor (NCDC) 
To study the role of PLC in the response to hydroperoxides, PLC inhibitor (NCDC) 
was used in the hydroperoxide-enhanced contraction. The concentration of NCDC 
used in the experiments referred to Tostes (Tostes et al., 1996). The experimental 
procedure to study the effects of PLC inhibitor was shown in Fig 12a, 12b. The 
contractile response to the hydroperoxide (0.05 mM H2O2 or tert.-BHP) was first 
tested. The response to hydroperoxides was expressed as a percentage of the 
contraction induced by KCl (30 mM) or PHE (1 µM). Then the segment was 
exposed to NCDC when the precontraction had reached a plateau. The response to 
NCDC was expressed as a percentage of the precontraction. When the response to 
NCDC was stable, 0.05 mM hydroperoxide (H2O2 or tert.-BHP) was added. The 
response to the hydroperoxide was expressed as a percentage of the precontraction 
with NCDC. 
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Fig 12a Typical model showing the effect of NCDC on the hydroperoxide-enhanced 
contraction (H2O2 and tert.-BHP) induced by KCl. S.C means standard contraction. The 
contraction was expressed in mN. The contractial response to the hydroperoxide in 
control group was expressed as a percentage of 30 mM KCl-precontraction. In the 
presence of NCDC, the response to H2O2 and tert.-BHP was expressed as a percentage of 
the contraction induced by KCl with NCDC. 
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Fig 12b Typical model showing the effect of NCDC on the hydroperoxide-enhanced 
contraction (H2O2 and tert.-BHP) induced by PHE. S.C means standard contraction. The 
contraction was expressed in mN. The contractial response to the hydroperoxide in 
control group was expressed as a percentage of 1 µM PHE-precontraction. In the 
presence of NCDC, the response to H2O2 and tert.-BHP was expressed as a percentage of 
the contraction induced by PHE with NCDC. 
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We observed that 0.02 mM NCDC practically abolished the contractile response 
induced by hydroperoxides (H2O2 and tert.-BHP) in KCl and PHE precontraction, 
respectively (Fig 12c, 12d). Additionally, NCDC did not cause effect on the 
contractile response elicited by 30 mM KCl, whereas NCDC significantly reduced 
the contraction induced by 1 µM PHE (Fig 12e). 
 
 
 
 
 
 
 
 
 
 
Fig 12c Effects of PLC inhibitor (0.02 mM NCDC) on H2O2-enhanced contraction. 
Results (Mean ± SD) were from 4 - 6 WT mice. The results were expressed as 
percentages of the contraction induced by 30 mM KCl (Control group) or by 
KCl + NCDC (NCDC group). *P<0.05, **P<0.01 compared with control. 
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Fig 12d Effects of PLC inhibitor (0.02 mM NCDC) on tert.-BHP-enhanced contraction. 
Results (Mean ± SD) were from 3 - 4 WT mice. The results were expressed as 
percentages of the contraction induced by 30 mM KCl (Control group) or by 
KCl + NCDC (NCDC group).*P<0.05 compared with control. 
 
 
 
 
 
 
 
 
 
Fig 12e Effects of NCDC on KCl- and PHE- precontraction. Results (Mean ± SD) were 
from 5 - 8 WT mice. In KCl group, the results were expressed as percentages of 30 mM 
KCl-induced contraction. The contraction of control was 6.6±3.8 mN and the response to 
NCDC was 6.7±3.8 mN. In PHE group, the results were expressed as percentages of the 
1 µM PHE-induced contraction. The contraction of control was 10.0±4.7 mN and the 
response to NCDC was 7.8±3.9 mN. Absolute data (mN) was used for comparison. 
**P<0.01 compared with control. 
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4.3.4.2 The effect of AT1 Receptor Antagonist on H2O2-enhanced 
Contraction 
To characterize the effect of AT1 receptor on the contractile response to H2O2, 
valsartan was used in the experiment. The concentration of valsartan used in the 
experiments referred to Arun et al (Arun et al., 2004). The experimental procedure 
was shown in Fig 13a. The contractile response to 0.05 mM H2O2 was firstly 
tested. The response to H2O2 was expressed as a percentage of the contraction 
induced by KCl (30 mM). Then the segment was exposed to KCl with 10 µM 
valsartan. When the precontraction had reached a plateau, 0.05 mM H2O2 was 
added. The contractile response to H2O2 was expressed as a percentage of the 
contraction induced by KCl with valsartan. We observed that valsartan 
significantly decreased the contraction of H2O2 (Fig 13b). 
 
The effect of 
valsartan on 
H2O2-stimulated 
contraction
S.C 
= 100%
Contraction 
by  H2O2
S.C 
= 100%
KCl Tyrode Tyrode KCl Tyrode + Valsartan
H2O2
Time
C
o
n
tr
a
ct
io
n
H2O2
C
o
n
tr
a
ct
io
n
 
Fig 13a Typical model showing the effect of valsartan on H2O2-enhanced contraction. 
S.C means standard contraction. The contraction was expressed in mN. The contractial 
response to H2O2 in control group was expressed as a percentage of the contraction 
induced by KCl (30 mM). In the presence of valartan, the response to H2O2 was 
expressed as a percentage of the contraction induced by KCl (30 mM) with valsartan. 
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Fig 13b The effect of AT1 recptor antagonist (10 µM valsartan) on H2O2-enhanced 
contraction. Results (Mean ± SD) were from 6 WT mice. The result was expressed as a 
percentage of the contraction induced by 30 mM KCl (Control group) or by 
KCl + valsartan (valsartan group). *P<0.05 compared with control. 
 
4.4 Effects of Hydroperoxides on the Contraction in GPx-1-/- 
Mouse Aorta 
4.4.1 Effects of Hydroperoxides on KCl-induced Contraction 
The experimental procedure of the contractile response to hydroperoxides in 
GPx-1-/- was the same as in WT (Fig 1). In GPx-1-/- mouse aorta, H2O2 increased 
KCl-precontraction at the concentrations of 0.01-0.25 mM, but produced 
relaxation at the concentration of 0.5 mM. The maximum response was reached at 
0.125 mM (143.9 ± 28.8 % of the response to 30 mM KCl, Fig 14a). At the 
concentration of 0.05 mM, H2O2 induced bigger contractile response in GPx-1-/- 
than in WT mice. tert.-BHP [0.01-0.125 mM] also enhanced 30 mM 
KCl-precontraction, reached a peak at 0.01 mM (123.8 ± 12.7 % of the response to 
30 mM KCl), and caused relaxation at 0.25 mM. At the concentration of 0.01 mM, 
tert.-BHP produced bigger contraction in GPx-1-/- than in WT mice (Fig 14b). 
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Fig 14a Concentration-response curve of H2O2 in GPx-1-/- and WT mouse aorta. Results 
(Mean ± SD) were from 5 - 8 mice. The results were expressed as percentages of the 
contraction with 30 mM KCl. *P<0.05 compared with WT. 
 
 
 
 
 
 
 
 
 
Fig 14b Concentration-response curve of tert.-BHP in GPx-1-/- and WT mouse aorta. 
Results (Mean ± SD) were from 4 - 10 mice. The results were expressed as percentages 
of the contraction with 30 mM KCl.*P<0.05 compared with WT. 
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4.4.2 Effects of Endothelium on Hydroperoxide-enhanced Contraction 
4.4.2.1 Effects of ACh on Hydroperoxide-enhanced Contraction 
The experimental procedure in GPx-1-/- was the same as in WT (Fig 3a). ACh 
[1-100 µM] induced relaxation in GPx-1-/- mouse aorta. There was no significant 
difference between GPX-1-/- and WT (Fig 15a). We selected 5 µM ACh for the 
further investigation on the hydroperoxide-enhanced contraction. As shown in 
Fig 15b, ACh [5 µM] significantly decreased the contraction induced by both 
hydroperoxides in GPx-1-/- mouse. The response to ACh in H2O2-enhanced 
contraction amounted to 90.0 ± 5.0 % of H2O2-enhanced contraction (p<0.01, 
n = 5). With tert.-BHP, the response amounted to 96.3 ± 3.6 % of 
tert.-BHP-enhanced contraction (p<0.05, n=5). 
 
 
 
 
 
 
 
 
 
 
Fig 15a Concentration-response curve of ACh in GPx-1-/- and WT mouse aorta. Results 
(Mean ± SD) were from 4 - 14 mice. The results were expressed as percentages of the 
contraction induced by 30 mM KCl. 
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Fig 15b Effects of 5 µM ACh on the hydroperoxide-enhanced contraction in GPx-1-/-. 
Results (Mean ± SD) were from 5 mice. The results were expressed as percentages of the 
contraction induced by 30 mM KCl. *P<0.05 compared with control. 
 
4.4.2.2 Effects of L-NAME on Hydroperoxide-enhanced Contraction 
In GPx-1-/- mouse aorta, L-NAME [0.05 mM] did not significantly increase 
30 mM KCl-induced contraction (Fig 16a). The response to 0.05 mM L-NAME 
amounted to 104.3 ± 11.0 % of KCl-precontraction (p>0.05, n = 7). Moreover, 
0.05 mM L-NAME did not significantly increase the hydroperoxide-enhanced 
contraction in GPx-1-/- mouse aorta (Fig 16b). 
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Fig 16a The effect of L-NAME on 30 mM KCl-precontraction in GPx-1-/- mouse aorta. 
Results (Mean ± SD) were from 7 mice. The results were expressed as percentages of the 
contraction with 30 mM KCl. The contraction of control was 8.5±6.8 mN and the 
response to L-NAME was 8.4±5.8 mN. Absolute data (mN) was used for comparison. 
 
 
 
 
 
 
 
 
 
 
Fig 16b The effect of 0.05 mM L-NAME on the hydroperoxide-enhanced contraction in 
GPx-1-/- mouse aorta. Results (Mean ± SD) were from 3 - 5 mice. The results were 
expressed as percentages of the contraction with 30 mM KCl. 
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4.4.2.3 Effects of Indomethacin on Hydroperoxide-enhanced Contraction 
The effect of indomethacin (COX inhibitor) in GPx-1-/- was studied. The 
experimental procedure was the same as in WT (Fig 8a). In this study, 
indomethacin [200 µM] significantly decreased the contraction induced by 30 mM 
KCl. In GPx-1-/- and WT mouse aorta, the response to indomethacin amounted to 
61.4 ± 11.8 % and 46.3 ± 11.0 % of KCl-precontraction, respectively. It seemed 
that the inhibition of indomethacin in WT was bigger than in GPx-1-/- mouse aorta, 
but there was no significant difference between WT and GPx-1-/- (Fig 17a). 
Furthermore, indomethacin significantly abolished the contractile response to 
H2O2 in GPx-1-/-, which was the same as in WT mouse aorta (Fig 17b). 
 
 
 
 
 
 
 
 
 
Fig 17a The effect of 200 µM indomethacin on KCl-induced contraction in WT and 
GPx-1-/-mouse aorta. Results (Mean ± SD) were from 3 mice. The results were expressed 
as percentages of the contraction induced by 30 mM KCl. 
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Fig 17b The effect of 200 µM indomethacin on H2O2-enhanced contraction in GPx-1-/- 
mouse aorta. Results (Mean ± SD) were from 4 mice. The results were expressed as 
percentages of the contraction induced by 30 mM KCl (Control group) or by 
KCl + indomethacin (indomethacin group). **P<0.01 compared with control. 
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4.5 Chemiluminescence Assays 
4.5.1 H2O2 on ROS Production in WT and GPx-1-/- Mouse Aorta 
Table 1 summarized the effects of the different concentrations of H2O2 on 
luminol-detectable ROS production in WT and GPx-1-/- mouse aorta. Without 
hydroperoxides, WT and GPx-1-/- mouse aorta alone can produce very low ROS 
(0.03 ± 0.009 and 0.02 ± 0.007 RLU, respectively) in the presence of luminol. In 
the presence of H2O2, CL signal significantly increased by a dose dependent way 
in WT and GPx-1-/- mouse aorta. Although the CL signal under control conditions 
(without tissue) increased in H2O2 dose-dependence, it was much lower than in 
WT and GPx-1-/- mouse aorta. The results indicated that the mouse aorta itself 
produced much ROS in the presence of H2O2. 
Luminol 
 
H2O2 
Control 
RLU 
WT 
RLU 
(RLU/mg) 
GPx-1-/- 
RLU 
(RLU/mg) 
0.01 mM 0.01 ± 0.003 0.07 ± 0.02 
(0.005 ± 0.002) 
0.08 ± 0.03 
(0.005 ± 0.002) 
0.05 mM 0.02 ± 0.002 13.1 ± 11.2 
(1.3 ± 1.7) 
14.1 ± 7.5 
(1.4 ± 0.7) 
0.125 mM 0.03 ± 0.006 393.4 ± 85.9 
(40.2 ± 16.0) 
197.1 ± 139.3 
(30.1 ± 29.3) 
0.25 mM 0.07 ± 0.01 368.2 ± 145.5 
(83.0 ± 63.3) 
494.7 ± 428.7 
(33.9 ± 31.1) 
0.5 mM 0.2 ± 0.05 1738.3 ± 958.9 
(182.6 ± 125.8) 
728.1 ± 518.9 
(101.2 ± 58.4) 
1 mM 343.3 ± 132.5 2559.8 ± 1928.7 
(182.9 ± 151.9) 
2845.3 ± 1467.0 
(265.6 ± 160.7) 
Table 1 H2O2 induced ROS production in WT and GPx-1-/- mouse aorta. CL was 
expressed as relative light units (RLU) and RLU/mg (Mean ± SD). Control, without tissue; 
WT, GPx-1-/- in the presence of WT and GPx-1-/- mouse aorta (n = 3 – 5). 
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Table 2 showed lucigenin-detectable superoxide production in WT and GPx-1-/- 
mouse aorta in the different concentrations of H2O2. Without hydroperoxides, 
GPx-1-/- and WT mouse aorta alone produced CL signal 0.1 ± 0.1 and 0.1 ± 0.06, 
respectively in the presence of lucigenin. Although lucigenin-detectable CL signal 
induced by higher concentrations of H2O2 was much lower than luminol-derived 
CL signal, WT and GPx-1-/- mouse aorta generated more superoxide in the 
presence of H2O2. There was insignificant difference between GPx-1-/- and WT 
mouse aorta. The results indicated that H2O2 generated more superoxide in WT 
and GPx-1-/- mouse aorta. 
Lucigenin 
 
H2O2 
Control 
RLU 
WT 
RLU 
(RLU/mg) 
GPx-1-/- 
RLU 
(RLU/mg) 
0.01 mM 0.02 ± 0.01 0.1 ± 0.06 
(0.007 ± 0.002) 
0.04 ± 0.003 
(0.004 ± 0.0005) 
0.05 mM 0.03 ± 0.005 0.1 ± 0.004 
(0.02 ± 0.02) 
0.1 ±0.01 
(0.02 ± 0.005) 
0.125 mM 0.06 ± 0.006 0.4 ± 0.08 
(0.04 ± 0.009) 
0.2 ±0.02 
(0.03 ± 0.006) 
0.25 mM 0.09 ± 0.007 0.3 ± 0.02 
(0.07 ± 0.03) 
0.2 ±0.03 
(0.02 ± 0.001) 
0.5 mM 0.1 ± 0.02 0.4 ± 0.2 
(0.08 ± 0.005) 
0.7 ±0.3 
(0.08 ± 0.003) 
1 mM 0.2 ± 0.004 0.4 ± 0.1 
(0.05 ± 0.02) 
0.5 ±0.09 
(0.1 ± 0.02) 
Table 2 H2O2 stimulated superoxide production in WT and GPx-1-/- mouse aorta. CL was 
expressed as relative light units (RLU) and RLU/mg (Mean ± SD). Control, without tissue; 
WT, GPx-1-/- , in the presence of WT and GPx-1-/- mouse aorta (n = 3 – 5). 
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4.5.2 tert.-BHP on ROS Production in WT and GPx-1-/- Mouse Aorta 
Table 3 summarized the effects of the different concentrations of tert.-BHP on 
luminol-detectable ROS production in WT and GPx-1-/- mouse aorta. In general, 
the luminol-derived CL signal was low in the different concentrations of tert.-BHP. 
Compared to H2O2, tert.-BHP generated much lower ROS in WT and GPx-1-/- 
mouse aorta. In higher concentrations of tert.-BHP (0.5, 1 mM), ROS production 
in GPx-1-/- was more than in WT mouse aorta, but there was not much difference 
for other concentrations. The results showed that tert.-BHP had no much effect on 
ROS generation in WT and GPx-1-/- mouse aorta. 
Luminol 
 
tert. – BHP 
Control 
RLU 
WT 
RLU 
(RLU/mg) 
GPx-1-/- 
RLU 
(RLU/mg) 
0.01 mM 0.01 ± 0.003 0.04 ± 0.02 
(0.003 ± 0.001) 
0.03 ± 0.005 
(0.004 ± 0.001) 
0.05 mM 0.01 ± 0.001 0.07 ± 0.06 
(0.008 ± 0.008) 
0.03 ± 0.004 
(0.005 ± 0.002) 
0.125 mM 0.07 ± 0.005 0.2 ± 0.05 
(0.009 ± 0.001) 
0.05 ± 0.02 
(0.007 ± 0.003) 
0.25 mM 0.4 ± 0.08 1.9 ± 0.9 
(0.2 ± 0.1) 
0.9 ± 1.3 
(0.2 ± 0.3) 
0.5 mM 1.3 ± 0.02 22.8 ± 12.8 
(4.2 ± 4.3) 
56.9 ± 22.7 
(10.9 ± 4.3) 
1 mM 0.5 ± 0.9 18.6 ± 2.8 
(1.7 ± 0.4) 
73.4 ± 51.3 
(11.1 ± 6.9) 
Table 3 tert.-BHP induced ROS production in WT and GPx-1-/- mouse aorta. CL was 
expressed as relative light units (RLU) and RLU/mg (Mean ± SD). Control, without tissue; 
WT, GPx-1-/- in the presence of WT and GPx-1-/- mouse aorta (n = 3 - 5). 
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Table 4 showed the lucigenin-detectable superoxide production in WT and GPx-1-
/-
 mouse aorta in the different concentrations of tert.-BHP. Although the 
lucigenin-derived CL signal was low in the different concentrations of tert.-BHP 
in WT and GPx-1-/- mouse aorta, tert.-BHP generated more superoxide in WT and 
GPx-1-/- mouse aorta. Compared to H2O2, tert.-BHP generated the similar amount 
of superoxide as H2O2. 
Lucigenin 
 
tert. – BHP 
Control 
RLU 
WT 
RLU 
(RLU/mg) 
GPx-1-/- 
RLU 
(RLU/mg) 
0.01 mM 0.02 ± 0.004 0.07 ± 0.02 
(0.009 ± 0.001) 
0.09 ± 0.03 
(0.02 ± 0.005) 
0.05 mM 0.03 ± 0.001 0.05 ± 0.02 
(0.007 ± 0.003) 
0.1 ± 0.02 
(0.04 ± 0.006) 
0.125 mM 0.03 ± 0.007 0.1 ± 0.03 
(0.01 ± 0.005) 
0.2 ± 0.1 
(0.07 ± 0.05) 
0.25 mM 0.02 ± 0.004 0.1 ± 0.06 
(0.02 ± 0.01) 
1.0 ± 1.5 
(0.2 ± 0.3) 
0.5 mM 0.02 ± 0.002 0.3 ± 0.06 
(0.04 ± 0.008) 
0.4 ± 0.1 
(0.1 ± 0.07) 
1 mM 0.02 ± 0.001 0.3 ± 0.07 
(0.04 ± 0.02) 
1.2 ± 1.4 
(0.3 ± 0.4) 
Table 4 tert.-BHP stimulated superoxide production in WT and GPx-1-/- mouse aorta. CL 
was expressed as relative light units (RLU) and RLU/mg (mean ± SD). Control, without 
tissue; WT, GPx-1-/- , in the presence of WT and GPx-1-/- mouse aorta (n = 3 – 5). 
 
4.5.3 Effects of Different Drugs Used in the Experiments on 
AAPH-induced ROS 
AAPH is a water-soluble azo compound which is used extensively as a free radical 
generator (Noguchi et al., 1998;Rice-Evans & Miller, 1994). Decomposition of 
AAPH produces molecular nitrogen and 2 carbon radicals. The carbon radicals 
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may combine to produce stable products or react with molecular oxygen to give 
peroxyl radicals. We studied the effects of different drugs used in the experiments 
on AAPH-induced ROS generation. As shown in Fig 21a, indomethacin and 
furegrelate had no effect on AAPH-induced ROS production. Other drugs 
including nifedipine, fasudil, 4-AP, quinacrine, meclofenamic, diclofenac, and 
valsartan had similar effects as indomethacin and furegrelate. However, dantrolene 
attenuated AAPH-induced ROS generation (Fig 21b). Since bupivacaine and 
NCDC were dissolved in ethanol and the same concentration of ethanol increased 
AAPH-induced ROS production as bupivacaine and NCDC (Fig 21c), it is 
possible that bupivacaine and NCDC increased AAPH-induced ROS generation 
by ethanol. 
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Fig 21a The effects of indomethacin and furegrelate on 
AAPH-induced ROS.
Fig 21b The effect of dantrolene on AAPH-induced ROS.
Fig 21c The effects of bupivacaine, NCDC, ethanol on 
AAPH- induced ROS.
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5 Discussion 
5.1 Hydroperoxide-induced Oxidative Stress and Arterial 
Contraction: Overview 
Under physiological conditions vascular cells produce reactive oxygen species 
(ROS), such as superoxide and hydrogen peroxide, as signalling molecules. 
However, excessive production of ROS results in oxidative stress. Since oxidative 
stress and associated oxidative damage lead to endothelial dysfunction, increased 
contractility, VSMC growth, lipid peroxidation and inflammation, they are 
involved in pathogenesis of many cardiovascular diseases, including hypertension, 
diabetes, and atherogenesis. 
 
In the arterial smooth muscle, many experiments have shown that low molecular 
hydroperoxides are able to induce vasoconstriction in relaxed arterial rings 
(Blumenstein, 2004;Heinle, 1984;Heinle, 1988). On the other hand, a number of 
studies have shown that in precontracted vessel segments, reactive oxygen 
metabolites produced relaxation, which in some cases seems to be mediated by 
endothelium-dependent mechanisms (Lacza et al., 2002;Matoba & Shimokawa, 
2003). This means that the findings regarding the effects of ROS and the 
metabolites on the function of the arterial smooth muscle are still controversial. 
 
In this study, hydrogen peroxide (H2O2) and tert.-BHP were used to study 
contractility effects on mouse aorta by inducing oxidative stress. H2O2 is 
metabolized to water by catalase and glutathione peroxidase (GPx). tert.-BHP is 
decomposed only by GPx. We observed a concentration-dependent contraction to 
H2O2 and tert.-BHP (0.01 mM-0.25 mM) in mouse aortic rings with the 
endothelium intact. However, we observed that H2O2 and tert.-BHP enhanced 
contraction much stronger in the mouse aorta without endothelium than with intact 
endothelium, suggesting that aortic contraction to H2O2 and tert.-BHP is affected 
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by the factors released from endothelium. These results also indicate that H2O2 and 
tert.-BHP can act directly on vascular smooth muscle to induce contraction. These 
findings are consistent with the reports in rat aorta (Blumenstein, 2004;Gao & Lee, 
2001;Taddei et al., 1998) , rat pulmonary arteries, abdominal aorta, and inferior 
vena (Pelaez et al., 2000). 
 
Despite the very different metabolism of both hydroperoxides, they revealed 
similar contractility effects in functional experiments. The different metabolism 
was also found when free radical production was studied. H2O2 produced much 
more ROS than tert.-BHP in mouse aorta, suggesting that the 
hydroperoxide-enhanced contraction is not related to the quantity of ROS 
production in the tissue. Although H2O2 and tert.-BHP increased ·O2– not very 
much in the extracellular space as was detected by lucigenin CL, ·O2– production 
by hydroperoxides from mouse aorta was much more than the control. It is 
possible that hydroperoxides increase enough intracellular ·O2– (Li et al., 2001), as 
a signal to increase [Ca2+]i, which would explain many cellular effects. 
 
In order to characterize underlying mechanisms in more details, we were 
especially interested in the participation of endothelium, and the characterization 
with some pharmacological effectors. The results of the corresponding 
experiments will be discussed in the following chapters. 
 
5.2 The Function of Endothelium in Hydroperoxide-enhanced 
Contraction 
5.2.1 NO limited the contraction enhanced by hydorperoxides. 
Endothelial cells synthesize and release various factors that regulate vascular tone, 
inflammation and angiogenesis. NO is the major vasodilative substance and 
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formed by endothelium cells from L-arginine via the enzymatic action of 
endothelial NO synthase (eNOS). According to our results, it seems that NO plays 
an important role in limiting the contraction induced by hydroperoxides. Firstly, 
Ach significantly decreased hydroperoxide-enhanced contraction. Secondly, 
inhibition of NOS by L-NAME increased that contraction. Thirdly, removal of the 
endothelium increased contraction induced by hydroperoxides. It is in contrast to 
very often mentioned opinion, that oxidative stress does impaire endothelial NO 
production. Some studies have reported that H2O2 and ·O2– inhibits the three major 
endothelium-dependent vasodilator pathways, i.e., NO [especially by the 
reaction: ·O2– + NO→ ONOO- (peroxynitrite)], prostacyclin, and EDHF. There is 
evidence that H2O2 appears to be involved in the reduced bioavailability of eNOS 
cofactors, which may induce uncoupled eNOS and lead to decreased production of 
NO (Ardanaz & Pagano, 2006). However, the data in this study showed that 
hydroperoxides did not inhibit NO release from endothelium. Additionally, some 
studies suggest that H2O2 can increase NO release in rat aorta, rabbit aorta and 
porcine coronary arteries (Bharadwaj & Prasad, 1995;Blumenstein, 
2004;Hayabuchi et al., 1998;Yang et al., 1999b). Thus, the effects of H2O2 on 
endothelium are dependent on the species, the artery, and the applied 
concentrations. 
 
5.2.2 Hydroperoxides Increased the Arterial Contraction by 
PLA2-COX-TXA2 Pathways. 
TXA2 is a powerful constrictor of vascular smooth muscle. It is a lipid mediator 
which originates from arachidonic acid (AA) metabolism through the 
cyclooxygenase (COX). There are two isoforms of COX: one constitutive 
(COX-1); the second one inducible (COX-2). COX-1 exists in most cells and 
COX-2 is induced in inflammatory cells. COX converts arachidonic acid (AA) to 
prostaglandin H2 (PGH2). PGH2 itself already possesses activity (Ge et al., 1995), 
or it may be metabolized by different synthases into prostaglandins (Fig 1), 
prostacycline (PGI2), or TXA2 (Reilly & FitzGerald, 1993). TXA2 can be released 
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from arterial endothelial and smooth muscle cells. Since enhanced TXA2 
production has been reported in several cardiovascular diseases, such as acute 
myocardial infarction and spontaneous hypertension (Paarlberg et al., 1998), 
oxidative stress appears to be a common denominator underlying endothelial 
dysfunction in these cardiovascular disease, the question arises whether 
hydroperoxides mediate arterial tone via TXA2 pathway. 
 
Phospholipids of cell membrane
Phospholipase A2
Arachidonic acid
PGH2
12-Lipoxygenase
5-Lipoxygenase
Cyclooxygenase
12-HETE Leukotrienes
(Increase vascular; 
Permeability)
PGI2
(vasodilator)
TXA2
(vasoconstrictor;
thrombotic)
PGF2 PGD2
(vasodilator; 
inhibits platelet 
aggregation)
PGE2
(vasodilator)
Endothelium 
Cell
 
Fig 1 Summary diagram of the mediators from phospholipids. HETE, 
hydroxyeicosatetraenoc acid. 
 
As seen from the results presented here, hydroperoxide-enhanced contraction was 
reduced by quinacrine (a PLA2 inhibitor). Although higher concentration (50 µM) 
of quinacrine decreased KCl-precontraction, low concentration (10 µM) of 
quinacrine had no effect on KCl-induced contraction. Moreover, 10 µM 
quinacrine significantly reduced H2O2-enhanced contraction. These results suggest 
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that PLA2 is involved in the contraction induced by hydroperoxides. It is still 
unknown how hydroperoxides activate PLA2. The possible mechanisms may be 
related to protein kinase C (Chakraborti & Michael, 1993) or P2 purinoceptors 
mediation. A number of reports have shown that COX is involved in ROS-induced 
contraction (Garcia-Cohen et al., 2000;Hibino et al., 1999;Rodriguez-Martinez et 
al., 1998). Our data showed that diclofenac, indomethacin and meclofenamic, 
three non-selective COX inhibitors, significantly inhibited the contraction of 
hydroperoxides. Although we found that the same concentration of indomethacin 
significantly decreased KCl-precontraction, the other two COX inhititors 
(diclofenac and meclofenamic) had no effects on KCl-induced contraction. These 
results confirm that COX metabolite-related signal pathways could participate in 
hydroperoxide-induced vessel contraction. Furthermore, we also found that 
bupivacaine and furegrelate, the TXA2 synthase inhibitors, significantly reduced 
the contraction of hydroperoxides. These results strongly suggest that TXA2 from 
PLA2-COX-TXA2 pathways may serve as the mediator of 
hydroperoxide-enhanced arterial smooth muscle contraction. TXA2 acts through 
specific G-protein coupling (Narumiya et al., 1999). Activation of TXA2 receptor 
(TP) leads to phospholipase C activation and release inositol 1,4,5-trisphosphate 
(IP3), which increases intracellular Ca2+ level to trigger the smooth muscle 
contraction (Habib et al., 1997). 
 
Although the antagonists of PLA2-COX-TXA2 pathways significantly reduced 
hydroperoxide-enhanced contraction, it is unclear whether they worked via the 
inhibition of the pathways or via antioxidant activity. In this point, we measured 
the effects of these drugs on AAPH-induced ROS production. Our data showed 
that these antagonists had no effects on AAPH-induced ROS, suggesting that they 
worked related to the pathways inhibited, not associated with antioxidant effects. 
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5.2.3 Angiotensin (Ang) II Involved H2O2 Increased Arterial 
Contraction. 
The renin-angiotensin system (RAS) plays an important role in the control of 
vascular tone. RAS is originating either from the kidney and blood or from the 
vessel wall itself (Dzau, 1988), so that  angiotensin II can be formed from isolated 
tissue. In the smooth muscle cells it acts on AT1 receptor (AT1R) to induce 
contraction, cell growth, migration and differentiation. Although Ang II has been 
reported to be involved in ROS generation by activating NAD(P)H (Touyz et al., 
2003), few show that oxidative stress activates AngII activity. 
 
Here, we showed that valsartan (AT1 inhibitor) decreased H2O2-enhanced 
contraction, suggesting that AT1 receptor seems to be involved in H2O2-enhanced 
contraction. In addition, valsartan may inhibit NAD(P)H oxidase activated by 
H2O2, which redues superoxide generation to decrease H2O2-enhanced contraction. 
Although ACE inhibitors and AT1 receptor antagonists have been reported to 
reduce oxidative stress in hypertensive patients (Baykal et al., 2003), the present 
experiment showed that valsartan did not reduce ROS induced by AAPH. 
 
5.3 Hydroperoxides Directly Act On the Arterial Smooth 
Muscle. 
The present study showed that hydroperoxides also enhanced contraction of the 
aorta with endothelium denuded, suggesting that hydroperoxides can act directly 
on vascular smooth muscle to induce contraction. [Ca2+]i plays a key role in 
smooth muscle contraction, but the effects of ROS on [Ca2+]i are contradictory. For 
example, Krippeit-Drews et al have reported that H2O2 can release Ca2+ from the 
sarcoplamic reticulum and mitochondria to increase [Ca2+]i in smooth muscle 
(Krippeit-Drews et al., 1995)
.
 In contrast, some studies have showed that ROS 
attenuate Ca2+ mobilization and decreases Ca2+ sensitivity of the contractile 
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machinery (Kimura et al., 2002). Here we will discuss separately the effects of 
hydroperoxides on transmembrane Ca2+ fluxes and intracellular Ca2+ liberation 
mechanisms in the smooth muscle cells of mice aorta. 
 
5.3.1 Transmembrane Ca2+ and Hydroperoxide-enhanced Contraction 
When the membrane is depolarized, extracellular Ca2+ enters the smooth muscle 
cell to induce contraction via the voltage-gated Ca2+ channels. L-type voltage Ca2+ 
channel is the main Ca2+ source for electrically evoked contraction in smooth 
muscle. Since nifedipine significantly decreased KCl-precontraction, the 
achievement of KCl-precontraction with nifedipine was followed by the effect of 
nifedipine on the response of hydroperoxides. The data showed that 
hydroperoxide-enhanced contraction was abolished by L-type voltage Ca2+ 
channel antagonist (nifedipine). It seems that extracellular Ca2+ is required for the 
hydroperoxide-induced contractions. Similar to our findings, Yang et al have 
shown that the absence of extracellular Ca2+ or employment of the Ca2+ channel 
antagonist, verapamil, inhibited the contractile effects of H2O2 on the dog canine 
basilar arteries (Yang et al., 1999a). Furthermore, our data showed that L-type 
Ca2+ channel antagonist, nifedipine, inhibited approximately 80% of the 
contractile effects of hydroperoxides on mouse aorta, suggesting that the influx of 
intracellular Ca2+ seems to play a principle role in the contractions. However, 
since nifedipine also decreased KCl-precontraction in this study, the inhibition of 
hydroperoxide-enhanced contraction by nifedipine might be associated with other 
pathways. On the other hand, it has been reported that extracellular Ca2+ ions are 
of minor importance for hydroperoxide-induced contraction in rabbit aorta, yet on 
the contrary, that Ca2+ from intracellular stores mediates the contraction in this 
aorta (Heinle, 1988). Additionally, some observations suggest that ROS inhibit 
Ca2+ channels activity and Ca2+ influx, which could contribute to reduced [Ca2+]i 
effects (Lounsbury et al., 2000;Thomas et al., 1998). When interpreting the results, 
however, it should be kept in mind that the experimental conditions, the contractile 
state of smooth muscle and different arteries may affect results. 
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5.3.2 Intracellular Ca2+ and Hydroperoxide-enhanced Contraction 
In agonist-induced contraction of smooth muscle, Ca2+ release from the 
sarcoplasmic reticulum is of great importance to stimulate contractile protein. Our 
data showed that dantrolene (an intracellular Ca2+ release inhibitor) decreased 
hydroperoxide-enhanced contraction, suggesting that hydroperoxides could 
stimulate Ca2+ release from intracellular stores. This assumption is supported by 
other findings (Heinle, 1988;Krippeit-Drews et al., 1995;Roychoudhury et al., 
1996a;Roychoudhury et al., 1996b)
.
 However, since dantrolene also significantly 
decreased KCl-precontraction, its specificity had to be questioned. Additionally, 
we have shown that dantrolene decreased ROS generation induced by AAPH. So 
it is not known whether dantrolene decreased hydroperoxide-enhanced contraction 
by antioxidant activity or by inhibition of intracellular Ca2+ release. 
 
PLC hydrolyzes PIP2, a phosphatidylinositol, into IP3 and DAG, which then 
modulate the activity of Ca2+ channels in the sarcoplasmic reticulum to release 
Ca2+. In our experiment, although phospholipase C (PLC) inhibitor (NCDC) 
significantly decreased PHE-precontraction, it had no effect on 
KCl-precontraction. Moreover, we found that NCDC abolished  the effects of 
hydroperoxides on KCl- and PHE-precontraction in mouse aorta, suggesting that 
the second messengers inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) 
seem to be involved in Ca2+ liberation from intracellular stores by hydroperoxides. 
This is agreement with the findings in porcine pulmonary artery (Shasby et al., 
1988). In addition, since H2O2 seems to provide a pathway for Ca2+ entry from the 
extracellular fluid via voltage-gated membrane Ca2+ channels, another mechanism 
is proposed that H2O2 may produce a Ca2+-induced Ca2+ release from intracellular 
stores (e.g., sarcoplasmic reticulum). Therefore the evidences presented in this 
work suggest that hydroperoxides possibly activate Ca2+ release from internal 
stores to increase [Ca2+]i by PLC activation. 
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5.3.3 Ca2+ Sensitization and Hydroperoxide-enhanced Contraction 
Although [Ca2+]i plays a crucial role for contractile machinery in the smooth 
muscle, it has been reported that the regulation of MLC phosphorylation and 
contractile force can be independent of changes in [Ca2+]i.  That means contractile 
force can be sustained at a constant [Ca2+]i,, which is referred to as Ca2+ 
sensitization (Somlyo & Somlyo, 2003). According to our data, hydroperoxides 
could increase Ca2+ sensitization by Rho kinase and PKC pathways. 
 
5.3.3.1 Rho Kinase Pathway 
Here, we showed that fasudil (Rho kinase inhibitor) decreased 
hydroperoxide-enhanced contraction, suggesting that Rho kinase may be related to 
this contraction. Rho is abundantly expressed in vascular smooth muscle (Hirata et 
al., 1992). It can increase SMC contractility independent of changes in 
intracellular calcium concentration via activation of Rho kinase, which in turn 
phosphorylates and inhibits MLC phosphatase and increases phosphorylated 
myosin (Kitazawa et al., 1991;Nishimura et al., 1996). Rho is reported to not only 
be involved in the pathophysiology of hypertension (Seasholtz et al., 2001), but 
also mediate NADPH oxidase to generate ROS (Napoli et al., 2001). However, 
since the same concentration of fasudil also significantly decreased 
KCl-precontraction, its specificity should be considered. 
 
On the other hand, since the contraction induced by KCl depends on calcium 
influx through voltage-operated Ca2+ channels, the result of inhibition of KCl 
precontraction by fasudil suggests that Ca2+ ions might induce Ca2+ sensitization. 
From this interesting result, it seems that Ca2+ influx may trigger its sensitization, 
rather like Ca2+-induced Ca2+ release. This is in agreement with the finding that 
membrane depolarization-induced contraction of rat caudal arterial smooth muscle 
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involves Rho-associated kinase (Mita et al., 2002). Thus, it seems that 
hydroperoxides not only directly activate Rho kinase pathway but also mediate 
Rho kinase pathway by increasing calcium influx through voltage-operated Ca2+ 
channels. 
 
5.3.3.2 PKC Pathway 
PKC is known to cause phosphorylation of the 20-kDa regulatory myosin light 
chain (MLC20). It may also activate mitogen-activated protein kinase (MAPK) 
leading to smooth muscle contraction without a significant increase in intracellular 
free Ca2+ (Pelaez et al., 2000). As discussed above (5.3.2), activation of PLC 
seems to be involved in hydroperoxide-enhanced contraction. The activation of 
PLC would also lead to activation of protein kinase C (PKC) and liberation of 
Ca2+ from intracellular stores. So we propose that hydroperoxides increase Ca2+ 
sensitization through activation of not only Rho kinase but also PKC pathway. The 
possible mechanism of H2O2 activating PKC in smooth muscle seems to increase 
activation of PI3-kinases and synthesis of one of the latter’s products, 
phosphatidylinositol 3,4,5-trisphosphate (PIP3), which in turn activates PKC-ξ 
(Nakanishi et al., 1993). 
 
5.3.4 Hydroperoxides May Inhibit Kv Channel on Smooth Muscle. 
Kv channels (voltage-activated K channels) are highly expressed in VSMC and 
contribute to membrane potential (Leblanc et al., 1994). Kv channels may partly 
limit the membrane depolarization that occurs during vasoconstriction since these 
channels are activated by depolarization. According to our study, we found that 
0.3 mM 4-AP (Kv channels inhibitor) increased PHE-induced contraction. Since 
4-AP inhibits Kv channels, and induces depolarization, extracellular Ca2+ enters 
into cells through voltage-gated Ca2+ channels to increase intracellular Ca2+, which 
induces contraction. 
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Cogolludo et al recently have reported that activation of NADPH oxidase and the 
subsequent production of hydrogen peroxide are involved in the Kv channel 
inhibition and the contractile response induced by TP receptor activation in rat PA 
(Cogolludo et al., 2006). In our study, we found that hydroperoxide-enhanced 
contraction was inhibited by 4-AP in PHE precontraction, but not in 30 mM KCl 
precontraction. This result suggests that hydroperoxides and 4-AP may inhibit the 
same K+ channels (Kv channels) in PHE precontraction. When Kv channels are 
inhibited by 4-AP, hydroperoxides have no effects on the same K+ channels. 
 
The mechanism by which hydroperoxides inhibit Kv channels is not known. 
Whether it is related to increased intracellular Ca2+ concentration (Cox & Petrou, 
1999), enhanced PKC activation (Clement-Chomienne et al., 1996) or specific 
oxidation amino acid residues of the Kv channel (Ciorba et al., 1999) must be 
elucidated by further experiments. 
 
5.4 The Role of Glutathione Peroxidase in 
Hydroperoxide-enhanced Contraction 
The enzyme glutathione peroxidase (GPx) is a selenocysteine-containing protein 
that serves an important role in the cellular defense against oxidant stress by 
utilizing reduced glutathione (GSH) to reduce H2O2, tert.-BHP to their 
corresponding alcohols (Ursini et al., 1995). GPx exists in several isoforms, and 
the most abundant intracellular isoform is GPx-1. In our study, the activity of GPx 
in GPx-1-/- aorta and liver is much lower than in WT mouse. Thus, a deficiency of 
GPx-1 would theoretically lead to an increase in ROS, or at least, to enhance 
oxidative imbalance in the presence of hydroperoxides. 
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Comparing the properties of WT and GPx-1-/- mice, there were interestingly only 
few differences. We found that in the presence of L-NAME, 
hydroperoxide-enhanced contraction did not significantly increase in GPx-1-/- as in 
WT mouse aorta, suggesting that GPx-1 possibly plays a role in protecting 
endothelium from oxidative damage. Our result is in full agreement with other 
studies that GPx-1-/- mice have an endothelial dysfunction caused by a deficiency 
in bioactive NO (Dayal et al., 2002;Forgione et al., 2002). Elevated levels of ROS 
can inactivate NO. Thus, the deficiency of GPx-1 impaired endothelial NO release. 
However, in all other experiments no significant differences were found. 
 
Since H2O2 is metabolized to water by catalase and GPx, whereas tert.-BHP is 
decomposed only by GPx, then tert.-BHP would theoretically lead to more 
oxidative stress and stronger contraction in GPx-1-/- mice. Again, there was no 
difference of hydroperoxide-enhanced contraction between WT and GPx-1-/- mice. 
The explanation for this finding is still unknown. One possibility is that GPx-1 is 
not very important for reducing hydroperoxides and other enzymes in GPx-1-/- 
mice may act in place of GPx-1, or that the remaining GPx activity in GPx-1-/- 
mice is still high enough for detoxifying the hydroperoxides. Another possibility is 
that hydroperoxides may enhance other signal pathways, not dependent on the 
amount of ROS produced by hydroperoxides. For example, H2O2 possibly plays a 
role for NADPH oxidase to produce enough ·O2–  to induce arterial contraction (Li 
et al., 2001). This would be consistent with the result that tert.-BHP produced 
much less ROS than H2O2, but both peroxides induced similar production of O2– 
as determined by lucigenin and similar contractility effects as determined in 
functional experiments. Thus, the total production of ROS during 
hydroperoxide-enhanced contraction is not determining the simulative effects. It is 
suggested that ·O2– might be the responsible species. However, this assumption 
has to be confirmed by further experiments. 
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5.5 Conclusion 
Hydroperoxides (H2O2, tert.-BHP) had multiple vasomotor actions. Different 
concentrations of hydroperoxides enhanced contraction in WT and GPx-1-/- mouse 
aorta. tert.-BHP produced similar amount of ·O2– and had the same vasoconstrictor 
effects as H2O2, but tert.-BHP produced much less ROS in the tissues than H2O2. 
Thus it seems that the amount of free radical generation is not related to effects of 
hydroperoxides
 
on arteries. It is possible that both hydroperoxides increase 
enough ·O2– as a signal to increase [Ca2+]i, thus enhancing arterial contraction. 
 
The results showed that obviously many different pathways are involved in 
mediating hydroperoxide-inducecd effects on arterial contraction, yet, a central 
common mechanism for H2O2 and tert.-BHP could be postulated. Fig 2 
summarizes the possible pathways as evaluated from the effects of the different 
drugs and as described on endothelial and smooth muscle cells, respectively. 
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Fig 2 The effects of hydroperoxides on the artery. The picture shows some effects of 
hydroperoxides on endothelial and smooth muscle cells. (AT1, angiotensin AT1-receptor; 
TP, T prostanoid receptor; Gq, G-protein; IP3, inositol 1,4,5-trisphosphate; DAG, 
diacylglycerol; EDHP, endothelium-derived hyperpolarizing factor; PKC, protein kinase 
C. 
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6 Summary 
Reactive oxygen species (ROS) are a class of molecules that are derived from the 
metabolism of oxygen and include free radical and nonracial species that are 
capable to oxidize molecular targets. Most important ROS include superoxide 
anion (·O2–), hydrogen peroxide (H2O2), hydroxyl anion (·OH) and reactive 
nitrogen species [e.g. nitric oxide (NO), peroxynitrite (ONOO-)]. All vascular cell 
types (endothelial cells, vascular smooth muscle cells, and adventitial fibroblast) 
produce ROS including H2O2. H2O2 is a cell-permeant and highly stable ROS 
generated mainly by dismutation of superoxide (·O2–) by superoxide dismutases 
(SOD). Although numerous studies have demonstrated the effects of H2O2 on 
endothelium and cultured smooth muscle cell signalling, its role in vascular tone 
as relaxantor or constricting factor is not well understood. Therefore we were 
interested to measure the effects of H2O2 and tert.-butylhydroperoxide on arterial 
contractial function in vitro and to characterize the signalling mechanisms using 
different pharmacological approaches. 
 
Firstly, the results showed that both hydroperoxides increased contraction induced 
by KCl and phenylephrine in a dose dependent way in WT mouse aorta. Secondly, 
inhibition of endothelial NO synthesis by L-NAME and denuded endothelium 
increased hydroperoxide-enhanced contraction. Additionally, ACh (0.1 mM) 
significantly decreased H2O2- and tert.-BHP-enhanced contraction. These results 
suggest that NO plays an important role in limiting the contraction induced by 
hydroperoxides. 
 
We investigated the involvement of phospholipaseA2-cyclooxygenase-
thromboxane A2 pathways in hydroperoxide-enhanced contraction. Our data 
indicated that hydroperoxide-enhanced contraction was reduced by quinacrine (a 
PLA2 inhibitor), suggesting the involvement of thromboxane A2 in this contraction. 
The results also showed that three non-selective cyclooxygenase inhibitors 
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(diclofenac, indomethacin and meclofenamic) significantly inhibited the 
contraction of hydroperoxides, confirming the participation of cyclooxygenase 
metabolite-related signal pathways in hydroperoxide-induced vessel contraction. 
Moreover, the thromboxane A2 synthase inhibitors (bupivacaine and furegrelate) 
were shown to reduce the contraction of hydroperoxides. Thus, hydroperoxides 
may activate phospholipase A2 – cyclooxygenase – thromboxane A2 pathways to 
increase contraction. These pathways seem to be related to endothelial cells. 
However their presence in smooth muscle can not be excluded. 
 
In addition, the present study showed that hydroperoxides also enhanced 
contraction in the mouse aorta with denuded endothelium, suggesting that 
hydroperoxides can act directly on vascular smooth muscle to induce contraction. 
Since [Ca2+]i plays a key role in smooth muscle contraction, we investigated the 
effects of hydroperoxides on transmembrane Ca2+ fluxes, intracellular Ca2+ 
liberation mechanisms as well as Ca2+ sensitization by different antagonists. 
 
Our data showed that hydroperoxide-enhanced contraction was abolished by 
L-type voltage Ca2+ channel antagonist (nifedipine), suggesting that extracellular 
Ca2+ is required for the hydroperoxide-induced contractions. Moreover, an 
intracellular Ca2+ release inhibitor (dantrolene) decreased 
hydroperoxides-enhanced contraction. Thus it seems that hydroperoxides stimulate 
also Ca2+ release from intracellular stores. The possible mechanism of Ca2+ 
liberation from intracellular stores by hydroperoxides seems to be involved in the 
second messengers of inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) 
because the study showed that NCDC [phospholipase C (PLC) inhibitor] abolished 
also the effects of hydroperoxides. PLC hydrolyzes PIP2, a phosphatidylinositol, 
into two second messengers, IP3 and DAG, which then modulate the activity of 
Ca2+ channels in the sarcoplasmic reticulum to release Ca2+. However, since the 
same concentrations of nifedipine and dantrolene also significantly decreased 
KCl-precontraction, its specificity should be questioned. 
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Additionally, we concluded that Ca2+ sensitization also might contribute to the 
hydroperoxide effects since the activation of PLC would lead to activation of 
protein kinase C (PKC), which activates mitogen-activated protein kinase (MAPK) 
leading to smooth muscle contraction increased by Ca2+ sensitization without a 
significant increase in intracellular free Ca2+. Furthermore, fasudil (Rho kinase 
inhibitor) decreased hydroperoxide-enhanced contraction. So we propose that 
hydroperoxides may increase Ca2+ sensitization through activation of not only 
PKC pathway but also Rho kinase. However, fasudil’s specificity should be 
considered because the same concentration of fasudil also significantly decreased 
KCl-precontraction. 
 
Kv channels (voltage-activated K channels) are highly expressed in VSMC and 
contribute to membrane potential. According to our study, 
hydroperoxide-enhanced contraction was inhibited by 4-AP in PHE precontraction, 
but not in 30 mM KCl precontraction. This result suggests that hydroperoxides 
and 4-AP may inhibit the same K+ channels (Kv channels) in PHE precontraction. 
When Kv channels are inhibited by 4-AP, hydroperoxides have no effects on the 
same K+ channels. 
 
The enzyme glutathione peroxidase serves an important role in the cellular defense 
against oxidant stress by utilizing reduced glutathione to reduce H2O2 and 
tert.-BHP to their corresponding alcohols. Using aortas from GPx-1-/- mice, in 
which the gene for GPx-1 was knocked out, we could show that glutathione 
peroxidase seems to protect endothelium from oxidative damage since we found 
that in the presence of L-NAME, hydroperoxide-enhanced contraction did not 
significantly increase in GPx-1-/- as in WT mouse aorta. H2O2 is metabolized to 
water by catalase and glutathione peroxidase, whereas tert.-BHP is decomposed 
only by GPx. Thus, a deficiency of GPx-1 would theoretically lead to an increase 
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in ROS. However, our data showed that there was no difference of 
hydroperoxide-enhanced contraction between WT and GPx-1-/- mice. According to 
the result, we propose that hydroperoxides enhance contraction not dependent on 
the quantity of ROS produced by hydroperoxides. Since it was described by others 
that hydroperoxides activate NAD(P)H oxidase to produce ·O2–, we postulated that 
as a common mechanism small amount of hydroperoxides may produce 
enough ·O2– to induce contraction. This is consistent with our results that H2O2 can 
produce much more ROS in mouse aorta than tert.-BHP (measured by luminol), 
yet, that both hydroperoxides induced a similar rate of ·O2– as detected by special 
luminescent dye lucigenin. Further experiments are needed to substantiate this 
type of thesis. 
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